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ABSTRACT: Concomitant inhibition of anaplastic lympho-
ma kinase (ALK) and bromodomain-4 (BRD4) is a potential
therapeutic strategy for targeting two key oncogenic drivers
that co-segregate in a signiﬁcant fraction of high-risk
neuroblastoma patients, mutation of ALK and ampliﬁcation
of MYCN. Starting from known dual polo-like kinase (PLK)-
1−BRD4 inhibitor BI-2536, we employed structure-based
design to redesign this series toward compounds with a dual
ALK−BRD4 proﬁle. These eﬀorts led to compound (R)-2-
((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-8-((4-methylthiophen-2-yl)methyl)-7,8-dihydropteri-
din-6(5H)-one (16k) demonstrating improved ALK activity and signiﬁcantly reduced PLK-1 activity, while maintaining BRD4
activity and overall kinome selectivity. We demonstrate the compounds’ on-target engagement with ALK and BRD4 in cells as
well as favorable broad kinase and bromodomain selectivity.
■ INTRODUCTION
Neuroblastoma is a pediatric cancer of neural crest origin and
is the most common extracranial solid tumor in childhood.1 In
high-risk patients, mutations within the kinase domain of the
anaplastic lymphoma kinase (ALK), such as ALKF1174L, co-
segregate with ampliﬁcation of the MYCN gene. Since the ALK
mutation increases transcription and expression of MYCN,
both oncogenic gene changes cooperate to upregulate this
well-established driver of neuroblastoma proliferation, resulting
in poor prognosis and clinical outcome.2
Several selective inhibitors of the ALK kinase have been
disclosed and entered clinical trials for diﬀerent indications.
However, crizotinib is clinically ineﬀective in neuroblastoma
and many second-generation ALK inhibitors are predicted to
be ineﬀective for neuroblastoma patients harboring the
F1174L mutation due to insuﬃcient inhibition of the mutant
kinase.3 Recently, the third-generation ALK inhibitor lorlatinib
was shown to potently inhibit ALKF1174L and has now entered
phase I clinical trials in relapsed or refractory neuroblastoma
patients.4
Inhibition of bromodomain-4 (BRD4) has recently emerged
as an essential transcriptional co-regulator of MYCN, and
inhibition of the bromodomain has been shown to be an
eﬀective therapeutic approach to target dysregulated MYCN in
neuroblastoma.5−7 Several compounds have progressed to
clinical trials for adult malignancies but have yet to reach
pediatric trials.8,9
It is increasingly recognized that targeting multiple pathways
that support cancer growth and survival is necessary to treat
aggressive cancers, provide a more durable response, and
overcome resistance.10 Given the clinical challenge that high-
risk neuroblastoma cases pose, combining ALK and BRD4
inhibition may represent an eﬀective therapeutic approach for
this high medical need. Combining both ALK and BRD4
inhibition would serve two purposes. First, it would target the
two most common and co-segregating events that drive high-
risk neuroblastoma and curb MYCN expression, potentially
resulting in strong antiproliferative or proapoptopic eﬀects.
Moreover, blocking two targets at once reduces the risk of
resistance to the therapy since the probability of clonal
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adaptation to targeted therapy is lower for combination
therapies.11
A key barrier in clinical implementation of new agents or
treatment strategies in children is that combination trials of
multiple drugs are challenging in pediatric patients. This is in
part due to the increased chance of oﬀ-target toxicity when two
agents are tested and length of trials because tolerable dose
must be established for each new agent separately in very small
patient populations.
An alternative approach to using two drugs in combination
is to explore dual inhibitors that block both targets of a
therapeutic combination, in the case of high-risk neuro-
blastoma, BRD4 and ALKF1174L. A dual inhibitor is likely to
reduce the liabilities associated with combination treatments,
particularly, oﬀ-target toxicities, drug−drug interactions, and
additive eﬀects. Furthermore, combinatorial treatment in the
form of a dual inhibitor reduces the length and complexity of
trials as well as costs.10,12,13
Dual inhibitors are thus an attractive therapeutic approach,
but the design and development of drugs that speciﬁcally
inhibit two targets, particularly, where these are structurally
distinct and not members of the same protein family, are
challenging. In particular, combining two pharmacophores into
a single druglike compound while also achieving selectivity and
physicochemical and pharmacokinetics properties consistent
with clinical development is regarded as very diﬃcult.10
However, precedent for dual kinase−bromodomain inhib-
itors has recently emerged. Through systematic screening
eﬀorts, Ember et al. and Ciceri et al. identiﬁed a total of 24
kinase inhibitors that interact with BRD4.14,15 Cocrystal
structures of these dual inhibitors revealed insights into how
the BRD4 and kinase pharmacophores can be combined into a
single druglike molecule. Although these reports provide
important precedence for dual kinase−bromodomain inhib-
ition and structural insights, the combination of bromodomain
and kinase inhibited by these dual inhibitors was discovered
Figure 1. Biochemical potencies of the dual PLK-1−BRD4 inhibitor BI-2536 and moieties of the molecule that form key interactions with BRD4
(orange) and the PLK-1 hinge region (violet).
Figure 2. X-ray structures of BI-2536 in complex with (a) BRD4 (4OGI) and (b) PLK-1 (2RKU) highlighting key interactions. (c) Docking pose
generated using Glide showing BI-2536 in complex with ALK (2XB7), highlighting key interactions. (d) Four chosen areas for modiﬁcation on BI-
2536.
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serendipitously by screening selective kinase inhibitors against
the bromo- and extra-terminal domain (BET) bromodomains.
To date, there are a few published reports of discovery eﬀorts
that aim to combine inhibition of a particular kinase with
bromodomain inhibition into a single dual inhibitor to explore
a speciﬁc disease hypothesis.16−18
Herein, we describe our eﬀorts to discover dual ALK−BRD4
inhibitors to target both oncogenic drivers of high-risk
neuroblastoma. We chose the dual polo-like kinase (PLK)-
1−BRD4 inhibitor BI-2536 as our starting point and
investigated if this inhibitor series can be reoptimized to
show potent inhibition of mutant (F1174L) ALK kinase,
reduced PLK-1 activity while maintaining BRD4 activity, and
acceptable kinome selectivity.
■ RESULTS AND DISCUSSION
Our goal at the start of the project was to discover starting
points that showed signiﬁcant activity against BRD4 and the
ALK kinase. We were particularly intrigued by the dual
kinase−bromodomain inhibitor BI-2536 (Figure 1). The
compound was discovered and developed as a PLK-1 kinase
inhibitor but was found to potently inhibit BRD4 by Knapp
and Schönbrunn’s labs.14,19,20 BI-2536 has been reported to
show high speciﬁcity within the kinase family, partially due to
the methoxy substituent. Some kinases are not able to
accommodate this substituent due to a steric clash with a
larger tyrosine or tryptophan residue in the hinge region.
Among the exceptions are PLK-1 and importantly ALK due to
the presence of a smaller leucine at this position.21,22 We thus
hypothesized that although BI-2536 showed excellent overall
kinase selectivity it may show suﬃcient activity against ALK
and ALKF1174L to serve as a starting point. We analyzed the
publicly available data, and indeed a Kd of 160 nM had been
disclosed for ALK.23 In our assays, BI-2536 showed
comparable, albeit modest, activity (IC50s of 390 and 190
nM against ALK and ALKF1174L, respectively).
In addition, we conﬁrmed inhibition of BRD4 and PLK-1. In
fact, the potency of BI-2536 against PLK-1 was beyond the
dynamic range of the assay (IC50 < 2.6 nM) consistent with a
published Kd of 0.19 nM.
23
BI-2536 thus was a suitable starting point for the discovery
of a dual ALK−BRD4 inhibitor, not least because it inhibited a
few other kinases apart from PLK-1 and ALK.23 We thus
decided to investigate if BI-2536 can be optimized toward a
Scheme 1
aReagents and conditions: (a) SOCl2, MeOH, 70 °C, 90%; (b) 1-iodo-2-methylpropane, K2CO3, dimethylformamide (DMF), 50 °C, 88%; (c)
LiOH, H2O, room temperature (rt), 71%; (d) 4-amino-1-methylpiperidine, HBTU, Et3N, DMF, rt, 77−86%; (e) SnCl2·2H2O, EtOAc/EtOH,
10:3, 50 °C, 53−55%; (f) 4-pyridylboronic acid, PdCl2(PPh3)2, Na2CO3, dioxane/water 6:1, 110 °C, 54−65%; (g) MeI, MeCN, 50 °C, 91−99%;
(h) NaBH4, MeOH, rt, 56−95%; (i) H2, PtO2, AcOH, 50 psi, 75−85%.
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dual ALK−BRD inhibitor. In particular, we sought to reduce
activity against PLK-1, improve ALK activity, and maintain
BRD4 activity. To analyze the scope for modiﬁcations as well
as derive design hypotheses, we ﬁrst analyzed the published
structures of BI-2536 bound to BRD4 and PLK-1.14,21 In
addition, we docked BI-2536 into ALK (2XB7) using Glide.
We chose this structure for our docking experiment due to
structural similarity between the ALK inhibitor NVP-
TAE68422 and BI-2536, in particular, the aminopyrimidine
hinge binding motif and the ortho-methoxy phenyl group.
In BRD4, the methyl amide moiety acts as the acetylated
lysine (KAc) mimetic, interacting with Asn140 (Figure 2a). As
described in more detail previously,14 additional interactions
arise between the aminopyrimidine group and conserved
waters in the ZA channel. The PLK-1-bound structure showed
that the aminopyrimidine forms the key interactions with the
hinge region of the kinase including Cys133 (Figure 2b).
Docking into ALK not surprisingly predicted that amino-
pyrimidine of BI-2536 interacted with the ALK hinge region
including residue Met1199 in a manner similar to that for
PLK-1 (Figure 2c). The amide carbonyl was also predicted to
interact with conserved water in the back of the ALK pocket.
Based on the ALK docking and BRD4 X-ray structure, we
wanted to maintain the key kinase and bromodomain binding
motifs on the dihydropteridinone core and thus decided to
leave these regions of the compound untouched.
Our analysis also suggested that several positions around the
core structure oﬀered signiﬁcant scope for modiﬁcation
(Figure 2d). The ﬁrst area chosen for modiﬁcation was the
(R)-ethyl group (R1), which ﬁts into a hydrophobic pocket in
both PLK-1 and BRD4. The docking of BI-2536 in ALK also
suggests that the (R)-ethyl is pointing toward a pocket formed
by residues Val1130, Ala1148, Lys1150, and Leu1196. It has
been reported that changing the chirality of the ethyl group has
little eﬀect on the potency at PLK-1 and BRD4, whereas
removing the group aﬀorded a 26-fold reduction in potency at
BRD4.24,25
We were also interested in the cyclopentyl substitution oﬀ
the dihydropteridinone core (R2), which has been shown to be
a region where BRD4 and PLK-1 selectivity can be tuned.24
For example, changing the cyclopentyl to a 3-bromobenzyl
group increases BRD4 aﬃnity due to improved hydrophobic
interactions with the WPF shelf but decreases PLK-1 activity,
suggesting that modiﬁcations in this region could be used to
improve selectivity against PLK-1.
Next, we considered the methoxy group at the R3 position.
Docking of BI-2536 suggests that the alkoxy group is pointing
toward a known region for achieving ALK selectivity (Figure
2c).21 The majority of kinases have a bulkier residue at this
region, allowing ALK selectivity to be achieved as seen with
ceritinib and alectinib.26,27 In addition, larger alkoxy groups
were known to improve interactions at BRD4.24 We thus
hypothesized that larger alkoxy groups will lead to increased
selectivity against PLK-1 while maintaining BRD4 activity.
The ﬁnal area chosen for modiﬁcation is the solvent channel
methylpiperidine group (R4). Published structure−activity
relationship (SAR) data for ALK inhibitors suggested that a
wide variety of groups are tolerated in this region.28−30 We
particularly decided to prepare analogues without the amide
group to reduce PLK-1 activity by removing a hydrogen-
bonding interaction with Leu59 and a water molecule in the
PLK-1 pocket.
Following this structure-based analysis and docking, we
decided to focus modiﬁcations on four areas (R1, R2, R3, and
R4) and to keep the dihydropteridinone core unchanged to
maintain the key kinase and bromodomain binding inter-
actions (Figure 2d).
Chemistry. We prepared a series of analogues of BI-2536
by adapting and optimizing previously described syntheses.31
For aniline intermediates containing the R3 and R4
modiﬁcations, two routes were used as shown in Scheme 1.
For the amide-containing intermediates, the isobutyl group was
ﬁrst introduced by alkylation to 3-hydroxy-4-nitrobenzoic acid
1 via protection and subsequent deprotection of the benzoic
Scheme 2
aReagents and conditions: (a) NaBH(OAc)3, NaOAc, 1,2-dichloroethane (DCE), rt, 16 h, 39−94%; (b) 2,4-dichloronitropyrimidine, NaHCO3,
cHex, 16 h, 50 °C, 34−90%; (c) Fe, AcOH, 3−4 h, 70 °C, 25−42%; (d) MeI, NaH, DMF, 0 °C to rt, 16 h, 59−75%; (e) conc. HCl, EtOH/
dioxane/H2O, 1:1:1, 120 °C, 24−48 h, 7−53%; (f) H2, 10% Pd·C, MeOH, rt, 1 h, 41−46%.
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acid. The 4-nitrobenzoic acid 3a was coupled to 4-amino-1-
methylpiperidine using O-(benzotriazol-1-yl)-N,N,N′,N′-tetra-
methyluronium hexaﬂuorophosphate (HBTU) to give amide
4a, followed by reduction using SnCl2 to give aniline 5a. The
ethoxy analogue 5b was made via the same route from
commercial compound 3b. The synthesis of anilines 10a and
10b began with a Suzuki coupling between an alkoxy-
nitrobenzene (6a and 6b) and 4-pyridineboronic acid.
Pyridines 7a and 7b were methylated to give 8a and 8b as
the iodonium salts and then partially reduced using sodium
borohydride (9a and 9b). Hydrogenation of the dihydropyr-
idine and nitro group gave aniline intermediates 10a and 10b.
Meanwhile, intermediates 15a−g were prepared according
to Scheme 2. The appropriate amino acids 11a−c underwent
reductive amination with various aldehydes to give inter-
mediates 12a−g followed by regioselective SNAr with 2,5-
dichloro-4-nitropyrimidine to give 13a−g. Reductive hetero-
cyclization using iron and acetic acid formed the dihydropter-
idinone scaﬀold (14a−g), which was methylated to give
intermediates 15a−g. The ﬁnal step was acid-promoted SNAr
between intermediates 15a−g and anilines 5a, 5b, 10a, and
10b to yield ﬁnal compounds 16a−l. Hydrogenation of
compounds 16f and 16h to remove the bromine yielded
compounds 16g and 16i.
A key obstacle to preparing a signiﬁcant number of
analogues at the R2 position was that this substituent was
introduced early and preparation of each example required ﬁve
steps (Scheme 2). To our surprise, there was no precedent for
synthetic routes for late stage variation at this position. To
facilitate preparation of these derivatives, we developed an
alternative approach. This approach maintained many
elements of the initial route (Scheme 3) but started with a
dimethoxybenzyl (DMB) protecting group at the R2 position.
This strategy allowed us to remove the DMB group by
reﬂuxing the advanced intermediate (20) in triﬂuoroacetyl
(TFA) and to subsequently introduce a wide range of R2
groups. A key challenge was that the reductive cyclization step
on intermediate 18 employing iron and acetic acid partially
removed the DMB group. We tested a range of hydrogenation
conditions and, gratifyingly, PtO2 and VO(acac)2 gave an
excellent yield of 98%.32 This route enabled us to prepare the
key intermediate 21 on a multigram scale and convert it into a
range of ﬁnal products (23a−f) in only two steps. Chiral shift
NMR and chiral high-performance liquid chromatography
(HPLC) conﬁrmed that no racemization took place under
either the strongly basic or strongly acidic conditions.
However, on a later repeat of this synthesis, we observed
that epimerization could occur during the alkylation of 19 to
yield 20. Reanalysis of previous batches conﬁrmed that no
epimerization was observed in the synthesis of the batch used
to prepare the compounds described in this article (Supp.
Figure 1). Furthermore, we reanalyzed products of reactions
obtained under similar alkylating conditions (Scheme 2),
conﬁrming that racemization had not occurred here either. All
ﬁnal products described here were thus unaﬀected by the
epimerization. However, due to the potential for racemization,
we sought to reoptimize this step. By reducing the number of
equivalents of sodium hydride or replacing this with a weaker
base such as sodium hydroxide, enantiomeric ratios of 9:1 or
greater could be obtained.
Biological Testing. Table 1 shows the derivatives of BI-
2536, modifying the R1, R2, R3, and R4 positions, and their
activities at ALKF1174L, BRD4, and PLK-1. The primary assays
for biochemical testing were LanthaScreen for ALKF1174L and
thermal shift against BRD4 (10 μM compound concentration).
For selected compounds, this was followed by isothermal
calorimetry against BRD4 and/or a PLK-1 Z-Lyte assay.
We started by analyzing the eﬀect of the amide functionality
in the solvent channel group (R4, Figure 2d). Removal of the
amide group (compound 16a) had little eﬀect against
ALKF1174L and BRD4 potency. However, consistent with our
hypothesis, it signiﬁcantly decreased PLK-1-1 activity. Based
on the measured IC50 value of 2.6 nM, 16a showed a four-fold
reduction in potency against PLK-1. The real eﬀect on PLK-1
potency of this structural change may be signiﬁcantly greater,
however, as the potency of BI-2536 is below the dynamic range
of our assay. Next, we analyzed the eﬀect of the R3 substituent
(Figure 2d) and prepared analogues with an ethoxy and an
isobutoxy group at this position. The ethoxy group on
compound 16c gave a small reduction in potency against
ALKF1174L but a greater decrease in PLK-1 potency. An
increase in the size of the group further to a butoxy group
(compound 16b) resulted in a much larger drop in potency
against ALKF1174L. For BRD4, increasing the group to ethoxy
and isobutoxy gave only a small decrease in activity, conﬁrming
the tolerance of larger groups at this position. Compound 16c
provided the best balance of potency and selectivity thus far, so
the ethoxy group was maintained.
Scheme 3
aReagents and conditions: (a) NaBH(OAc)3, NaOAc, DCE, rt, 16 h, 97%; (b) 2,4-dichloronitropyrimidine, NaHCO3, cHex, 16 h, 50 °C, 78%; (c)
H2, PtO2, VO(acac)2, tetrahydrofuran (THF), 98%; (d) MeI, NaH, DMF, 0 °C to rt, 16 h, 86%; (e) TFA, 80 °C, 4 h, 66%; (f) R
2−X, NaH, DMF,
rt, 16 h, 37−68%; (g) conc. HCl, EtOH/dioxane/H2O, 1:1:1, 120 °C, 24−48 h, 9−32%.
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We started testing the eﬀect of the R1 group by removing the
(R)-ethyl group (16e). This removal reduced potency at
BRD4 and PLK-1 very likely due to the loss of favorable
interactions with the aforementioned pockets in BRD4 and
PLK-1. Similarly, removal of the (R)-Et group also reduced
ALKF1174L potency 3-fold. We also synthesized the opposite
enantiomer 16d, which also signiﬁcantly reduced potency at all
three targets. The reduction in PLK-1 and BRD4 activity was
not in agreement with a published study but consistent with
loss of productive interactions of the (R)-Et group with both
PLK-1 and BRD4 and supported by modeling, which suggests
that the ethyl group is too big to be accommodated on the
lower face of the PLK-1 pocket. Finally, we analyzed
substitution at the R2 position. Compounds 16f and 16g
with a 3-bromobenzyl and benzyl group, respectively,
maintained BRD4 activity and led to a 30−40-fold decrease
of the PLK-1 activity, as expected from previous reports.24
Compounds 16f and 16g were equipotent in ALKF1174L
activity, compared with 16c. Importantly, the divergent SAR
between ALK and PLK-1 with 16f and 16g supported our
hypothesis that it is possible to optimize the ALK/PLK-1
selectivity window at the R2 position.
To conclude this initial SAR investigation, we combined
modiﬁcations that showed a decrease in PLK-1 potency.
Compounds 16h and 16i with the combined modiﬁcations of
the benzyl or 3-bromobenzyl group at R2, ethoxy group at R3,
and removal of the amide at R4 gave a greater decrease in PLK-
1 activity (>100−200-fold). With benzyl compound 16i, we
Table 1. Structure−Activity Relationships of the R1, R2, R3, and R4 Groups
aData represents the geometric mean; see Supp. Table 1 for full statistics. n.d. = not determined. bTm shift determined at compound concentration
of 10 μM, n = 2.
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also saw a 2-fold increase in ALKF1174L potency and maintained
potent BRD4 activity. This was the ﬁrst analogue demonstrat-
ing greater potency at ALKF1174L than at PLK-1.
R2 SAR. So far, the greatest change in PLK-1 activity
resulted from modifying the cyclopentyl to a benzyl or 3-
bromobenzyl group (Table 1). Further inspection of this
region in ALK and PLK-1 structures shows that PLK-1 has a
larger phenylalanine residue (Phe183) at the bottom of this
pocket compared with a smaller leucine residue (Leu1286) in
ALK (Figure 3a,b). We hypothesized that PLK-1 inhibition
would be less tolerant to substitution at the R2 position due to
this geometric constraint compared to that in the more open
ALK structure. To investigate this hypothesis further, we
performed docking studies of 3-bromobenzyl analogue 16h in
PLK-1 (Figure 3c). The aminopyrimidine moiety was still
predicted to bind to the hinge region including Cys133, but a
shift in the core was observed. Additionally, the core of the
molecule adopts a more strained, puckered conformation. Both
diﬀerences from the observed binding mode were likely caused
by clashes of the bromobenzyl group with the side chain of
Phe183 and were consistent with the decrease in activity
observed with benzyl analogues 16f−i. We thus decided to
explore if this key amino acid diﬀerence can be exploited to
discover compounds with improved ALK potency and PLK-1
selectivity.
To enable structure-based design, we attempted to solve
cocrystal structures of our compounds bound to ALK.
However, these attempts failed, likely due to the still modest
activity. Due to the lack of structural information, we decided
to probe the ALK pocket through systematic synthesis and
testing.
Using the modiﬁed route in Scheme 3 to facilitate
preparation of analogues at the R2 position, we prepared
compounds 23a−c to analyze the eﬀect of diﬀerent
substitutions at the 3-benzyl position. While these compounds
maintained the BRD4 activity, we did not observe improve-
ments in ALKF1174L potency or PLK-1 selectivity, aside from
compound 23b that contains a 3-cyanobenzyl group. The
PLK-1 IC50 was 1.8 μM, a >700-fold decrease from starting
compound BI-2536, leading to an improved (5-fold) ALK
selectivity over PLK-1. Compound 23b demonstrated that
PLK-1 activity can be substantially reduced by varying this
position, but we were still yet to ﬁnd a group that achieved this
while maintaining or improving ALKF1174L potency. Next, we
considered changing the substitution position on the benzyl
ring. However, the ortho- and para-bromobenzyls 23d and 23e
showed no improvement in ALKF1174L potency compared with
meta-analogue 16h and were still not as potent as
unsubstituted benzyl analogue 16i.
We then considered heterocycle substituents. Thiazole 23f
showed a decrease in ALKF1174L activity, but exploring
thiophenes proved to be more productive. Compound 16j
gave encouraging IC50s against ALK
F1174L and BRD4, yet the
ALK/PLK ratio dropped to 1:1. Following from this result, we
moved the methyl group around the thiophene ring. Derivative
16k with the methyl group at the 4-position showed potent
inhibition of ALKF1174L (IC50 = 17 nM) and through this gain
in potency also a 7-fold selectivity window over PLK-1.
Gratifyingly, the compound retained BRD4 activity (Table 2).
We next determined the cocrystal structures of 16i and 16k
with BRD4 (Figure 4 and Supp. Table 3). The compounds
bound into the acetyllysine-binding site with the methyl amide
moiety retaining the key hydrogen bond interaction with
asparagine N140. The methyl amide and pyrimidine moieties
in both compounds retain interactions with conserved waters
in the BRD4 pocket, whereas the thiophene and benzyl R2
substituents are situated in the hydrophobic WPF shelf region.
With compound 16k, we had a compound in hand that
showed satisfactory IC50s against ALK
F1174L and BRD4 and a
selectivity window over PLK-1. We decided to proﬁle 16k
further by examining the physicochemical properties and
broader kinase and bromodomain selectivity. Lipophilicity was
measured using the SiriusT3 potentiometric method, giving a
high log P of 6.1 (Table 3). It is notable that the measured log
D7.4 of 4.2 is signiﬁcantly lower due to protonation of the
piperidine basic center, which can also account for the good
solubility. In addition, the compound shows good permeability
as measured in a PAMPA permeability assay.
Next, we considered the broader kinase and bromodomain
selectivity of 16k to assess if the compound maintained the
selectivity across both protein families. Compound 16k was
ﬁrst tested against a panel of BET and non-BET
bromodomains. In this panel, 16k exhibited excellent BET
family selectivity, in common with BI-2536 and other BET
inhibitors (Figure 5a and Supp. Table 4).14,33,34 We then
tested 16k against the DiscoverX scanEDGE panel of 97
kinases at a single point concentration of 1 μM.35 Gratifyingly,
only four kinases were identiﬁed as hits, conﬁrming that we
had maintained broad kinome selectivity; the greatest
inhibition was observed for ALK wild type (WT) and PLK-1
Figure 3. Surfaces of (a) ALK (2XB7) and (b) PLK-1 (2RKU) highlighting residues Leu1256 and Phe183. (c) Docking pose generated using Glide
showing 16h (orange) in complex with PLK-1 (2RKU), overlaid with X-ray structure of BI-2536 (yellow) in PLK-1 (2RKU).
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followed by insulin receptor (INSR) and PLK-3 (Figure 5b
and Table 4). We attributed the observed broad kinase
selectivity of 16k at least partially to be due to the ethoxy
group.21,27 This was based on the observation that the kinases
that showed signiﬁcant inhibition (ALK, PLK-1, PLK-3, and
INSR) indeed feature a smaller leucine residue in the hinge
Table 2. Structure−Activity Relationships of the R2 Groupc
aData represents the geometric mean; see Supp. Table 2 for full statistics. n.d. = not determined. bFinal compounds synthesized using Scheme 2.
cTm shift determined at compound concentration of 10 μM, n = 2.
Figure 4. (a) Cocrystal structure of 16i with BRD4 (6Q3Y) and associated |2FO| − |FC| reﬁned electron density map contoured at 1σ. (b) Cocrystal
structure of 16k with BRD4 (6Q3Z) and associated |2FO| − |FC| reﬁned electron density map contoured at 1σ.
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region that can accommodate the ethoxy group (Supp. Table
5).
Table 3. Physicochemical Properties of 16k
parameter result
solubility (HPLC)a 90 μM
PAMPA pH7.4 49 × 10−6 cm/s
log P 6.1
logD7.4 4.2
aSolubility measured via an in-house HPLC method from phosphate
buﬀer at pH 7.4.
Figure 5. (a) Screening of 16k against a panel of 25 bromodomains, showing ΔTm as circles. Larger circles indicate greater ΔTm. (b) Screening of
16k against the DiscoverX scanEDGE panel of 97 kinases at a single point concentration of 1 μM. Larger circles indicate a stronger hit.
Table 4. Kds of 16k against the Kinase Screening Hits
kinase hits at 1 μM (% control) Kd (nM)
ALK WT 7.1 89
INSR 25 190
PLK-1 1 11
PLK-3 25 160
ALKF1174L 23
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Demonstrating Target Engagement in Cells. We next
tested our lead compounds in the cellular context to conﬁrm
that we had on-target engagement of ALK and BRD4 in cells.
We ﬁrst tested the eﬀect of compound 16k on autophosphor-
ylation of the ALKF1174L mutant in Kelly neuroblastoma cells
using an meso-scale discovery (MSD) assay (Figure 6). For
comparison, we also tested our starting point BI-2536 and the
Food and Drug Administration-approved ALK inhibitor
ceritinib26 as a positive control. Compound 16k showed
inhibition of ALKF1174L phosphorylation levels, in line with
what was expected from the biochemical IC50 and representing
a signiﬁcant improvement from starting compound BI-2536.
We also measured the cellular potency of our lead
compounds against BRD4 and ALK WT using NanoBRET
assays (Figure 7 and Supp. Table 6). Compound 16k showed a
cellular potency of 470 nM against ALK WT and 260 nM
against BRD4. The BRD4 cellular potency was comparable to
that of starting compound BI-2536, consistent with the
compound’s minimal disruption to the key interactions with
the BRD4 pocket. The results of the ALK autophosphorylation
assay and NanoBRET experiments demonstrated that 16k
inhibited both ALKF1174L and BRD4 in cells.
Cellular Kinase Selectivity. The observation that the
biochemical potency of 16k translated eﬃciently into cellular
assays with a relatively minor drop-oﬀ consistent with other
ALK inhibitors prompted us to investigate the selectivity
against PLK-1 in cells. Despite very good overall selectivity in
the DiscoverX scan, 16k showed similar Kds for the ALK
F1174L
mutant and PLK-1 (23 vs 11 nM, Table 4). However, given
the small cellular drop-oﬀ for ALK mentioned above, we
speculated that a larger drop-oﬀ for PLK-1 may lead to a better
selectivity window. To investigate this hypothesis, we
investigated markers of PLK-1 inhibition in cells, namely,
mitotic arrest in the G2/M phase and increased concentrations
of PLK-1, cyclin B1, and phosphohistone H3. Indeed, BI-2536
has been published to show eﬀects on these markers at
concentration around 50 nM, which is a 250-fold drop-oﬀ from
its Kd of 0.19 nM.
36 As compound 16k is structurally similar to
BI-2536, we would expect to see a similar potency drop-oﬀ in
cells, in this case to >2.5 μM. To assess the cellular selectivity,
we assessed the eﬀect of compounds 16k and BI-2536 on
HeLa cells. Consistent with data mentioned above, BI-2536
induced mitotic arrest and increased concentrations of PLK-1,
cyclin B1, and phosphohistone H3 at a concentration as low as
50 nM (Figure 8).36 In addition, we observed an increase in
PLK-1 phosphorylation at sites T210 and S137. In strong
contrast, compound 16k did not cause an increase in levels of
these mitotic markers and phosphorylation sites up to
concentrations of 10 μM and thus well beyond the
concentration where ALKF1174L and BRD4 are inhibited in
the cellular context. Quantitative analysis of the cell cycle
distribution by ﬂow cytometry supported the data obtained by
Western blot analysis (Supp. Figure 2).
Based on the cellular data, the combination of the reduction
in PLK-1 activity and the improvement in ALKF1174L activity
thus resulted in a >10−20-fold selectivity window for
ALKF1174L over PLK-1 in cells. Compound 16k thus
Figure 6. ALK MSD immunoassay measuring ALK phosphorylation in the Kelly cell line. The plot shows the ratio of phosphorylated ALK to total
ALK.
Figure 7. NanoBRET data for lead compounds 16i−k against ALK and BRD4 in HEK293T cells.
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represented a signiﬁcant step toward discovering drugs that
concomitantly target mutant ALK and BRD4.
■ CONCLUSIONS
To our knowledge, we report the ﬁrst combined ALK−BRD4
inhibitor (16k). Moreover, our work is one of the few
examples where medicinal chemistry design was applied to
combine inhibition of a speciﬁc kinase (in this case ALK) with
BRD4 inhibition to discover a dual inhibitor for a clearly
deﬁned therapeutic hypothesis.
We started from the known dual inhibitor BI-2536 that
inhibits PLK-1 and BRD4. Interestingly, although tuning the
PLK-1 and BRD4 activity of BI-2536 has been disclosed,
changing the kinase activity to another target and hence to a
new dual kinase−bromodomain combination has not been
reported.24,25 Exploring a structure-based design, we discov-
ered compounds with signiﬁcantly improved ALK activity and
greatly reduced PLK-1 activity while maintaining BRD4
potency and overall kinome selectivity. Our lead compound
demonstrates on-target engagement of ALK and BRD4 in
cellular assays and favorable broad kinase and bromodomain
selectivity. In particular, the compound showed selectivity over
PLK-1 in cells underlining the design eﬀort to change the
kinase selectivity from PLK-1 to ALK.
Our work also highlighted the well-known challenges of
designing and discovering dual inhibitors that inhibit two,
structurally distinct proteins. A particular challenge is to
incorporate two distinct pharmacophores that ensure not only
potent inhibition of both targets but also selectivity within
these protein families (in our case, kinases and bromodo-
mains) into one druglike compound.
Despite these challenges, we achieved signiﬁcant steps
toward a dual ALK and BRD4 inhibitor. Key to this progress
was choosing a starting point that contained an alkoxy group
that is tolerated only by a few kinases including ALK and PLK-
1. By maintaining this throughout, we achieved a compound
with satisfactory overall kinome selectivity.
Our main optimization goal starting from BI-2536 was to
signiﬁcantly improve ALK activity and PLK-1 selectivity. The
challenge here was that key regions of BI-2536 had to remain
untouched to maintain the BRD4 activity. In particular, the
methyl substituent that points toward the gatekeeper and the
ethyl group would have been promising places to improve
activity for ALK and selectivity over PLK-1. However, both
moieties are essential for potent binding to BRD4 and could
hence not be changed. Crucially, our structure-based analysis
also suggested that the R2 substituent can be modiﬁed without
losing BRD4 activity and that optimizing this part of the
molecule was a promising approach to achieve our goal of
shifting kinase selectivity, as exempliﬁed by 16k.
We thus conclude that, not surprisingly, the quality and
properties of the selected starting point matter even more for
programs aiming at dual inhibitors since the options for
chemical optimization will be signiﬁcantly more limited.
Directly related to that, the challenge of discovering dual
inhibitors is somewhat less daunting when both targets
tolerated a range of diﬀerent chemotypes and inhibitors, thus
increasing the chance that a starting point with already
favorable properties can be explored.
■ EXPERIMENTAL SECTION
General Synthetic Information. All anhydrous solvents and
reagents were obtained from commercial suppliers and used without
further puriﬁcation. All reactions were carried out under a positive
pressure of N2, and moisture-sensitive reagents were transferred via a
syringe. Evaporation of solvent was carried out using a rotary
evaporator under reduced pressure at a bath temperature of up to 60
°C. Column chromatography was carried out using a Biotage SP4
puriﬁcation system using Biotage SNAP Kp-Si cartridges. Semi-
preparative separations were carried out using a 1200 series
preparative HPLC over a 15 min gradient elution (Grad15-
min20mls.m) from 90:10 to 0:100 water/methanol (both modiﬁed
with 0.1% formic acid) at a ﬂow rate of 20 mL/min. Microwave-
assisted reactions were carried out using a Biotage Initiator microwave
system. In general, the course of reactions was followed by thin layer
chromatography or mass spectroscopy. All ﬁnal compounds were
puriﬁed to ≥95% purity.
NMR spectra were recorded on a Bruker AMX 500 (500 MHz)
spectrometer using a deutrated solvent. NMR data is presented in the
form of chemical shift δ (multiplicity, coupling constants, and
integration) for major diagnostic protons, given in parts per million
(ppm) relative to tetramethylsilane as an internal standard. High-
resolution mass spectrometry (HRMS) was assessed using an Agilent
1200 series HPL and diode array detector coupled to a 6120 time-of-
ﬂight mass spectrometer with a dual multimode atmospheric-pressure
chemical ionization/electrospray ionization (ESI) source. Analytical
separation was carried out at 30 °C on a Merck Purospher STAR
column (RP-18e, 30 × 4 mm2) using a ﬂow rate of 1.5 mL/min in a 4
min gradient elution; solvents: aqueous (0.1% formic aid) and
methanol, monitored at a wavelength of 254 nm. Optical rotation was
determined by an ADP 440 polarimeter. Speciﬁc rotations [α]D are
given in deg cm3/(g dm).
Methyl 3-Isobutoxy-4-nitrobenzoate (2). Step 1: 3-Hydroxy-4-
nitrobenzoic acid 1 (500 mg, 2.73 mmol) was suspended in MeOH
(0.1 M), and SOCl2 (0.40 mL, 5.46 mmol) was added slowly at 0 °C.
The reaction was heated at reﬂux for 4 h. Upon completion, the
volatiles were removed in vacuo and the residue was triturated with
diethyl ether. The resulting solid was ﬁltered and dried under vacuum
to aﬀord methyl 3-hydroxy-4-nitrobenzoate (HCl salt) as a yellow
solid (576 mg, 90%). δH (500 MHz, CDCl3): 10.51 (s, 1H), 8.18 (d, J
= 8.5 Hz, 1H), 7.84 (d, J = 1.6 Hz, 1H), 7.62 (dd, J = 8.5, 1.6 Hz,
1H), 3.97 (s, 3H). Step 2: To the crude product in DMF (0.1 M) was
added K2CO3 (592 mg, 4.28 mmol) and 1-iodo-2-methylpropane
(142 μL, 1.20 mmol), and the reaction was stirred at 50 °C for 16 h.
Upon completion, EtOAc was added and the mixture was washed
with water (×2) and brine (×1), dried over MgSO4, ﬁltered, and
concentrated in vacuo. The residue was puriﬁed by Biotage column
chromatography (cHex/EtOAc, 0−20%) to aﬀord 2 as a colorless oil
(158 mg, 0.62 mmol 73%). δH (500 MHz, CDCl3): 7.81 (d, J = 8.2
Hz, 1H), 7.71 (d, J = 1.6 Hz, 1H), 7.67−7.64 (m, 1H), 3.96 (s, 3H),
3.92 (d, J = 6.3 Hz, 1H), 2.20−2.11 (m, 1H), 1.05 (d, J = 6.9 Hz,
6H).
Figure 8. Induction of mitotic arrest by BI-2536 and 16k in HeLa
cells. Changes in the fraction of cells arrested in mitosis were analyzed
by Western blots against phosphorylation sites pT210 and pS137 and
mitotic markers PLK-1, cyclin B1, and phosphohistone H3.
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3-Isobutoxy-4-nitrobenzoic Acid (3a). To 2 (150 mg, 0.59 mmol)
in a solvent mixture of THF/H2O (1:1, 0.1 M) was added LiOH (142
mg, 5.92 mmol), and the reaction was stirred for 18 h. Upon
completion, the aqueous layer was acidiﬁed with 1 M HCl until pH 1
was reached and extracted with EtOAc (×3). The combined organic
phases were dried over MgSO4, ﬁltered, and concentrated in vacuo to
aﬀord 3a as a yellow solid (100 mg, 0.42 mmol, 71%). δH (500 MHz,
CDCl3): 7.85 (d, J = 8.2 Hz, 1H), 7.79 (d, J = 1.3 Hz, 1H), 7.76 (dd, J
= 8.2, 1.3 Hz, 1H), 3.95 (d, J = 6.3 Hz, 1H), 2.23−2.14 (m, 1H), 1.08
(d, J = 6.9 Hz, 6H).
3-Isobutoxy-N-(1-methylpiperidin-4-yl)-4-nitrobenzamide (4a).
To a solution of 3a (50 mg, 0.21 mmol) in DMF (0.1 M) was
added HBTU (127 mg, 0.33 mmol), Et3N (58 μL, 0.41 mmol), and 1-
methylpiperidin-4-amine (23.9 mg, 0.21 mmol), and the reaction was
stirred for 18 h. Upon completion, the reaction mixture was
partitioned between EtOAc and water and the aqueous layer was
extracted with EtOAc (×2). The organic phases were combined, dried
over MgSO4, ﬁltered, and concentrated in vacuo. The residue was
puriﬁed by Biotage column chromatography (dichloromethane
(DCM)/MeOH, 0−10%) to aﬀord 4a as a yellow solid (60 mg,
0.18 mmol, 86%). HRMS (ESI +ve): found [M]+ 336.1927,
[C17H24N3O4]
+ requires 336.1923; δH (500 MHz, CDCl3) 7.81 (d,
J = 8.2 Hz, 1H), 7.55 (d, J = 1.6 Hz, 1H), 7.28 (dd, J = 8.2, 1.6 Hz,
1H), 6.44 (d, J = 7.6 Hz, 1H), 4.06−3.97 (m, 1H), 3.92 (d, J = 6.3
Hz, 2H), 2.94 (d, J = 11.7 Hz, 2H), 2.37 (s, 3H), 2.30−2.25 (m, 2H),
2.18−2.10 (m, 1H), 2.09−2.03 (m, 2H), 1.78−1.69 (m, 2H), 1.04 (d,
J = 6.6 Hz, 6H).
3-Ethoxy-N-(1-methylpiperidin-4-yl)-4-nitrobenzamide (4b). 4b
was synthesized in 77% yield (orange solid, 111 mg, 0.36 mmol)
according to the same procedure as 4a, from 3b (100 mg, 0.47 mmol)
and 1-methylpiperidin-4-amine (54.1 mg, 0.47 mmol). HRMS (ESI
+ve): found [M]+ 308.1624 [C15H21N3O4]
+ requires 308.1610; δH
(500 MHz, CDCl3): 7.82 (d, J = 8.2 Hz, 1H), 7.58 (d, J = 1.9 Hz,
1H), 7.23 (dd, J = 8.2, 1.9 Hz, 1H), 5.99 (d, J = 7.3 Hz, 1H), 4.26 (q,
J = 7.2 Hz, 2H), 4.05−3.94 (m, 1H), 2.87 (d, J = 11.2 Hz, 2H), 2.33
(s, 3H), 2.19 (t, J = 11.2 Hz, 2H), 2.10−2.03 (m, 2H), 1.65−1.56 (m,
2H), 1.49 (t, J = 6.9 Hz, 3H).
4-Amino-3-isobutoxy-N-(1-methylpiperidin-4-yl)benzamide
(5a). 4a (60 mg, 0.18 mmol) was dissolved in a solvent mixture of
EtOAc/EtOH (10:3, 0.1 M) to which tin(II) chloride dihydrate (202
mg, 0.89 mmol) was added. The reaction was stirred for 16 h at 50
°C. Upon completion, NaHCO3 was added and the aqueous layer was
extracted with EtOAc (×3). The combined organic phases were dried
over MgSO4, ﬁltered, and concentrated in vacuo to aﬀord 5a as a
yellow solid (30 mg, 99 μmol, 55%). HRMS (ESI +ve): found [M]+
306.22161, [C17H28N3O2]
+ requires 306.2176; δH (500 MHz, CDCl3)
7.32 (d, J = 1.9 Hz, 1H), 7.10 (d, J = 8.2, 1.9 Hz, 1H), 6.66 (d, J = 8.2
Hz, 1H), 5.86 (d, J = 6.3 Hz, 1H), 4.12 (s, 2H), 4.02−3.92 (m, 1H),
3.83 (d, J = 6.3 Hz, 2H), 2.83 (d, J = 11.0 Hz, 2H), 2.31 (s, 3H),
2.22−2.09 (m, 3H), 2.07−2.00 (m, 2H), 1.57 (qd, J = 11.7, 3.6 Hz,
2H), 1.04 (d, J = 6.9 Hz, 6H).
4-Amino-3-ethoxy-N-(1-methylpiperidin-4-yl)benzamide (5b).
5b was synthesized in 53% yield (yellow solid, 46 mg, 0.16 mmol)
according to the same procedure as 5a, from 4b (95 mg, 0.31 mmol).
HRMS (ESI +ve): found [M]+ 278.1874 [C15H23N3O2]
+ requires
278.1863; δH (500 MHz, CDCl3) 7.33 (d, J = 1.9 Hz, 1H), 7.11 (dd, J
= 8.1, 1.9 Hz, 1H), 6.66 (d, J = 8.1 Hz, 1H), 5.86 (d, J = 7.3 Hz, 1H),
4.18−4.09 (m, 4H), 4.05−3.94 (m, 1H), 2.86 (d, J = 11.0 Hz, 2H),
2.33 (s, 3H), 2.23−2.18 (m, 2H), 2.04 (d, J = 10.4 Hz, 2H), 1.61−
1.57 (m, 2H), 1.45 (t, J = 6.9 Hz, 3H).
4-(3-Ethoxy-4-nitrophenyl)pyridine (7a). 4-Bromo-2-ethoxy-1-ni-
trobenzene 6a (1.5 g, 6.10 mmol), pyridine-4-ylboronic acid (749 mg,
6.10 mmol), Na2CO3 (1.1 g, 10.0 mmol), and Pd(PPh3)2Cl2 (160 mg,
0.23 mmol) were dissolved in a solvent mixture of dioxane/water
(6:1, 0.38 M) and heated at 110 °C for 45 min under microwave
irradiation. Upon completion, the mixture was partitioned between
EtOAc and water and the aqueous phase was extracted with EtOAc
(×2) and DCM (×1). The organic phases were combined, dried over
MgSO4, ﬁltered, and concentrated in vacuo. The residue was puriﬁed
by Biotage column chromatography (DCM/MeOH, 9:1) to aﬀord 7a
as a yellow solid (81 mg, 3.32 mmol, 54%). HRMS (ESI +ve): found
[M]+ 245.0917 [C13H12N2O3]
+ requires 245.0921; δH (500 MHz,
CDCl3): 8.74 (dd, J = 4.4, 1.19 Hz, 2H), 7.96 (d, J = 8.5 Hz, 1H),
7.49 (d, J = 4.4, 1.6 Hz, 2H), 7.27−7.24 (m, 2H), 4.28 (q, J = 7.0 Hz,
2H), 1.53 (dt, J = 7.0 Hz, 3H)
4-(3-Methoxy-4-nitrophenyl)pyridine (7b). 7b was synthesized in
65% yield (yellow solid, 200 mg, 0.87 mmol) according to the same
procedure as 7a, from 4-chloro-2-methoxy-1-nitrobenzene 6b (250 g,
1.33 mmol) and pyridine-4-ylboronic acid (164 mg, 1.33 mmol).
HRMS (ESI +ve): found [M]+ 231.0803 [C12H10N2O3]
+ requires
231.0770; δH (500 MHz, CDCl3): 8.74−8.72 (dd, J = 4.4, 1.6 Hz,
2H), 7.99 (dd, J = 8.8 Hz, 1H), 7.51 (dd, J = 4.4, 1.6 Hz, 2H), 7.28−
7.25 (m, 2H), 4.05 (s, 3H).
4-(3-Ethoxy-4-nitrophenyl)-1-methylpyridin1-ium Iodide (8a). 7a
(600 mg, 2.47 mmol) and methyl iodide (0.54 mL, 8.65 mmol) were
dissolved in acetonitrile (0.1 M), and the reaction was heated for 4 h
at 50 °C. Upon completion, the mixture was concentrated in vacuo to
aﬀord 8a as a yellow solid (945 mg, 2.45 mmol, 99%). HRMS (ESI
+ve): found [M]+ 259.1076 [C14H15N2O3]
+ requires 259.1082; δH
(500 MHz, MeOD4) 8.99 (d, J = 6.7 Hz, 2H), 8.48 (d, J = 6.7 Hz,
2H), 7.99 (d, J = 8.5 Hz, 1H), 7.79 (d, J = 1.8 Hz, 1H), 7.65 (dd, J =
8.5, 1.8 Hz, 1H), 4.46 (s, 3H), 4.38 (q, J = 6.9 Hz, 2H), 1.49 (t, J =
6.9 Hz, 3H).
4-(3-Methoxy-4-nitrophenyl)-1-methylpyridin1-ium Iodide (8b).
8b was synthesized in 91% yield (yellow solid, 295 mg, 0.79 mmol)
according to the same procedure as 8a, from 7b (200 mg, 0.87 mmol)
and methyl iodide (0.19 mL, 3.04 mmol). HRMS (ESI +ve): found
[M]+ 245.0920 [C13H13N2O3]
+ requires 245.0926; δH (500 MHz,
MeOD4) 8.99 (d, J = 6.7 Hz, 2H), 8.49 (d, J = 6.7 Hz, 2H), 8.01 (d, J
= 8.2 Hz, 1H), 7.81 (d, J = 1.9 Hz, 1H), 7.66 (dd, J = 8.2, 1.9 Hz,
1H), 4.45 (s, 3H), 4.10 (s, 3H).
4-(3-Ethoxy-4-nitrophenyl)-1-methyl-1,2,3,6-tetrahydropyridine
(9a). 8a (945 mg, 2.45 mmol) was dissolved in MeOH (0.05 M) and
cooled to 0 °C. NaBH4 (943 mg, 24.5 mmol) was slowly added in
batches, and the reaction was stirred at rt for 2 h. The reaction was
quenched with 1 M HCl, and MeOH was partially removed in vacuo.
The residue was partitioned between EtOAc and 1 M NaOH until pH
12 was reached. The EtOAc layer was washed with 1 M NaOH, dried
over MgSO4, ﬁltered, and concentrated in vacuo to give 9a as a yellow
oil (609 mg, 2.32 mmol, 95%). HRMS (ESI +ve): found [M]+
263.1387 [C14H18N2O3]
+ requires 263.1390; δH (500 MHz, CDCl3):
7.85 (d, J = 8.5 Hz, 1H), 7.04−7.00 (m, 2H), 6.21−6.18 (m, 1H),
4.20 (q, J = 6.9 Hz, 2H), 3.17−3.14 (m, 2H), 2.69 (t, J = 5.7 Hz, 2H),
2.60−2.56 (m, 2H), 2.43 (s, 3H), 1.49 (t, J = 6.9 Hz, 3H).
4-(3-Methoxy-4-nitrophenyl)-1-methyl-1,2,3,6-tetrahydropyri-
dine (9b). 9b was synthesized in 56% yield (yellow oil, 80 mg, 0.32
mmol) according to the same procedure as 9a, from 8b (212 mg, 0.57
mmol). HRMS (ESI +ve): found [M]+ 245.1239 [C13H13N2O3]
+
requires 249.1243; δH (500 MHz, CDCl3): 7.85 (d, J = 8.5 Hz, 1H),
7.04 (d, J = 1.9 Hz, 1H), 7.02 (dd, J = 8.5, 1.9 Hz, 1H), 6.20 (tt, J =
3.5, 1.6 Hz, 1H), 3.96 (s, 3H), 3.16 (d, J = 2.85 Hz, 2H), 2.71−2.67
(m, 2H), 2.60−2.56 (m, 2H), 2.42 (s, 3H).
2-Ethoxy-4-(1-methylpiperidin-4-yl)aniline (10a). 9a (600 mg,
2.32 mmol) and PtO2 (158 mg, 0.70 mmol) were dissolved in acetic
acid (0.03 M), and the mixture was purged with N2. The mixture was
placed under 50 psi of H2 gas at rt for 16 h. The mixture was ﬁltered
through celite, washed with MeOH, and concentrated in vacuo. The
residue was puriﬁed by Biotage column chromatography (DCM/
MeOH, 9:1) to aﬀord 10a as an orange oil (410 mg, 1.75 mmol,
75%). HRMS (ESI +ve): found [M]+ 235.1819 [C14H22N2O]
+
requires 235.1809; δH (500 MHz, CDCl3) 6.68−6.60 (m, 3H), 4.05
(q, J = 7.0 Hz, 2H), 3.20 (d, J = 11.7 Hz, 2H), 2.46−2.38 (4H, m)
2.29 (td, J = 11.7, 2.5 Hz, 2H), 1.99−1.89 (m, 2H), 1.88−1.82 (m,
2H), 1.42 (t, J = 7.0 Hz, 3H).
2-Methoxy-4-(1-methylpiperidin-4-yl)aniline (10b). 10b was
synthesized in 85% yield (yellow oil, 30 mg, 0.14 mmol) according
to the same procedure as 10a, from 9b (600 mg, 2.32 mmol). HRMS
(ESI +ve): found [M]+ 221.1649 [C13H20N2O]
+ requires 221.1648;
δH (500 MHz, CDCl3) 6.65−6.61 (m, 3H), 3.83 (s, 3H), 3.08 (dt, J =
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12.1, 2.5 Hz, 2H), 2.46−2.37 (m, 1H), 2.38 (s, 3H), 2.16 (td, J =
12.1, 4.1 Hz, 2H), 1.91−1.81 (m, 4H).
(R)-Methyl 2-(Cyclopentylamino)butanoate (12a). (R)-Methyl 2-
aminobutanoate 11a (HCl salt, 1.50 g, 9.77 mmol) and cyclo-
pentanone (0.87 mL, 9.77 mmol) were dissolved in DCE (0.1 M).
The reaction was cooled to 0 °C, and NaOAc (801 mg, 9.77 mmol)
and NaBH(OAc)3 (4.14 g, 19.5 mmol) were added. The reaction was
stirred at rt for 16 h. Upon completion, sat. NaHCO3 was added and
the aqueous phase was extracted with DCM (×3). The combined
organic phases were washed with water, dried over MgSO4, ﬁltered,
and concentrated in vacuo to aﬀord compound 12a as a yellow oil
(1.45 g, 7.83 mmol, 80%). HRMS (ESI +ve): found [M]+ 186.1498,
[C10H20NO2]
+ requires 186.1494; [α]D
21.8: −12.0 (c 1.0, MeOH); δH
(500 MHz, CDCl3): 3.73 (s, 3H), 3.22 (t, J = 6.6 Hz, 1H), 2.97
(quin, J = 6.7 Hz, 1H), 1.83−1.60 (m, 6H), 1.55−1.47 (m, 2H),
1.35−1.27 (m, 2H), 0.92 (t, J = 7.6 Hz, 3H).
(S)-Methyl 2-(Cyclopentylamino)butanoate (12b). 12b was
synthesized in 88% yield (brown oil, 1.42 g, 7.68 mmol) according
to the same procedure as 12d, from (S)-methyl 2-aminobutanoate
11b (HCl salt, 1.34 g, 8.72 mmol) and cyclopentanone (0.78 mL,
8.72 mmol). HRMS (ESI +ve): found [M]+ 186.1498, [C10H20NO2]
+
requires 186.1494; [α]D
21.9: +11.8 (c 1.0, MeOH); δH (500 MHz,
CDCl3): 3.71 (s, 3H), 3.20 (t, J = 6.6 Hz, 1H), 2.96 (quin, J = 6.7 Hz,
1H), 1.83−1.58 (m, 6H), 1.55−1.47 (m, 2H), 1.35−1.27 (m, 2H),
0.91 (t, J = 7.6 Hz, 3H).
Methyl Cyclopentylglycinate (12c). 12c was synthesized in 39%
yield (yellow oil, 535 mg, 3.40 mmol) according to the same
procedure as 12d, from glycine methyl ester 11c (HCl salt, 1.10 g,
8.77 mmol) and cyclopentanone (0.62 mL, 7.01 mmol). HRMS (ESI
+ve): found [M]+ 158.1176, [C8H15NO2]
+ requires 158.1176; δH
(500 MHz, CDCl3): 3.73 (s, 3H), 3.42 (s, 2H), 3.07 (quin, J = 6.5
Hz, 1H), 1.85−1.77 (m, 2H), 1.75−1.66 (m, 2H), 1.60−1.50 (m,
2H), 1.40−1.32 (m, 2H).
(R)-Methyl 2-((3-Bromobenzyl)amino)butanoate (12d). 12d was
synthesized in 92% yield (yellow oil, 1.37 g, 4.79 mmol) according to
the same procedure as 12a, from (R)-methyl 2-aminobutanoate 11a
(HCl salt, 800 mg, 5.21 mmol) and 3-bromobenzaldehyde (0.61 mL,
5.21 mmol). HRMS (ESI +ve): found [M]+ 286.0431,
[C12H17BrNO2]
+ requires 286.0437; [α]D
21.9: +22.9 (c 1.0, MeOH);
δH (500 MHz, CDCl3): 7.52 (t, J = 1.6 Hz, 1H), 7.38 (dt, J = 7.9, 1.6
Hz, 1H), 7.28−7.25 (m, 1H), 7.20−7.17 (m, 1H), 3.80 (d, J = 13.2
Hz, 1H), 3.74 (s, 3H), 3.60 (d, J = 13.2 Hz, 1H), 3.20 (t, J = 6.6 Hz,
1H), 1.76−1.62 (m, 2H), 0.96 (t, J = 7.6 Hz, 3H).
(R)-Methyl 2-(((3-Methylthiophen-2-yl)methyl)amino)butanoate
(12e). 12e was synthesized in 74% yield (yellow oil, 720 mg, 3.17
mmol) according to the same procedure as 12d, from (R)-methyl 2-
aminobutanote 11a (HCl salt, 500 mg, 4.27 mmol) and 3-
methylthiophene-2-carbaldehyde (0.46 mL, 4.27 mmol). HRMS
(ESI +ve): found [M]+ 228.1061, [C11H18NO2S]
+ requires
228.1053; [α]D
22.6: +23.6 (c 1.0, MeOH); δH (500 MHz, CDCl3):
7.10 (d, J = 5.0 Hz, 1H), 6.78 (d, J = 5.4 Hz, 1H), 3.93 (d, J = 13.9
Hz, 1H), 3.76−3.73 (m, 4H), 3.27 (t, J = 6.6 Hz, 1H), 2.17 (s, 3H),
1.74−1.62 (m, 2H), 0.95 (t, J = 6.9 Hz, 3H).
(R)-Methyl 2-(((4-Methylthiophen-2-yl)methyl)amino)butanoate
(12f). 12f was synthesized in 95% yield (yellow oil, 1.70 g, 7.48
mmol) according to the same procedure as 12d, from (R)-methyl 2-
aminobutanote 11a (HCl salt, 1.20 mg, 7.81 mmol) and 4-
methylthiophene-2-carbaldehyde (0.83 mL, 6.72 mmol). HRMS
(ESI +ve): found [M]+ 228.1062, [C11H18NO2S]
+ requires
228.1053; [α]D
22.5: +28.4 (c 1.0, MeOH); δH (500 MHz, CDCl3):
6.78 (t, J = 1.2 Hz, 1H), 6.73 (s, 1H), 3.98 (dd, J = 14.0, 0.8 Hz, 1H),
3.78 (dd, J = 14.0, 0.8 Hz, 1H), 3.74 (s, 3H), 3.29 (t, J = 6.5 Hz, 1H),
2.22 (d, J = 1.2 Hz, 3H), 1.74−1.62 (m, 2H), 0.95 (t, J = 7.6 Hz, 3H).
(R)-Methyl 2-(((5-Methylthiophen-2-yl)methyl)amino)butanoate
(12g). 12g was synthesized in 77% yield (yellow oil, 892 mg, 3.92
mmol) according to the same procedure as 12d, from (R)-methyl 2-
aminobutanote 11a (HCl salt, 600 mg, 5.12 mmol) and 5-
methylthiophene-2-carbaldehyde (0.43 mL, 4.10 mmol). HRMS
(ESI +ve): found [M]+ 228.1049, [C11H18NO2S]
+ requires
228.1053; [α]D
22.2: +23.6 (c 1.0, MeOH); δH (500 MHz, CDCl3):
6.68 (d, J = 3.2 Hz, 1H), 6.58−6.55 (m, 1H), 3.95 (d, J = 13.9 Hz,
1H), 3.75 (d, J = 13.9 Hz, 1H), 3.73 (s, 3H), 3.28 (t, J = 6.6 Hz, 1H),
2.45 (s, 3H), 1.89 (s, 1H), 1.74−1.61 (m, 2H), 0.94 (t, J = 6.9 Hz,
3H).
(R)-Methyl 2-((2-Chloro-5-nitropyrimidin-4-yl)(cyclopentyl)-
amino)butanoate (13a). 12a (700 mg, 3.78 mmol) and NaHCO3
(635 mg, 7.6 mmol) were dissolved in cyclohexane (0.1 M) and
stirred for 30 min. 2,4-Dichloro-5-nitropyrimidine (806 mg, 4.16
mmol) was added, and the reaction was stirred at 60 °C for 16 h.
Upon completion, the reaction mixture was ﬁltered, washed with
CH2Cl2, and concentrated in vacuo. The residue was puriﬁed by
Biotage column chromatography (cHex/EtOAc, 0−20%) to aﬀord
the title compound 13a as a yellow solid (1.03 g, 2.99 mmol, 79%).
HRMS (ESI +ve): found [M]+ 343.1165, [C14H20ClN4O4]
+ requires
343.1173; [α]D
21.8: +228.5 (c 1.0, MeOH); δH (500 MHz, CDCl3):
8.67 (s, 1H), 3.78−3.72 (m, 1H), 3.76 (s, 3H), 3.60−3.52 (m, 1H),
2.47−2.36 (m, 1H), 2.26−2.17 (m, 1H), 2.09−1.98 (m, 1H), 1.98−
1.91 (m, 1H), 1.84−1.56 (m, 6H), 1.05 (t, J = 7.6 Hz, 3H).
(S)-Methyl 2-((2-Chloro-5-nitropyrimidin-4-yl)(cyclopentyl)-
amino)butanoate (13b). 13b was synthesized in 32% yield (yellow
solid, 830 mg, 2.42 mmol) according to the same procedure as 13d,
from 12b (1.40 g, 7.56 mmol) and 2,4-dichloro-5-nitropyrimidine
(1.61 g, 8.31 mmol). HRMS (ESI +ve): found [M]+ 343.1171,
[C14H20ClN4O4]
+ requires 343.1173; [α]D
22.0: −229.9 (c 1.0, MeOH);
δH (CDCl3, 500 MHz): 8.67 (s, 1H), 3.78−3.72 (m, 1H), 3.76 (s,
3H), 3.60−3.51 (m, 1H), 2.46−2.36 (m, 1H), 2.25−2.17 (m, 1H),
2.09−2.01 (m, 1H), 1.99−1.90 (m, 1H), 1.84−1.47 (m, 6H), 1.05 (t,
J = 7.6 Hz, 3H).
Methyl N-(2-Chloro-5-nitropyrimidin-4-yl)-N-cyclopentylglyci-
nate (13c). 13c was synthesized in 78% yield (yellow solid, 416
mg, 1.32 mmol) according to the same procedure as 13d, from 12c
(265 mg, 1.69 mmol) and 2,4-dichloro-5-nitropyrimidine (360 mg,
1.85 mmol). HRMS (ESI +ve): found [M]+ 315.0843,
[C12H15ClN4O4]
+ requires 315.0860; δH (CDCl3, 500 MHz): 8.65
(s, 1H), 4.17 (s, 2H), 3.98−3.88 (m, 1H), 3.79 (s, 3H), 2.16−2.07
(m, 2H), 1.78−1.70 (m, 2H), 1.64−1.53 (m, 4H).
(R)-Methyl 2-((3-Bromobenzyl)(2-chloro-5-nitropyrimidin-4-yl)-
amino)butanoate (13d). 13d was synthesized in 90% yield (yellow
oil, 1.81 g, 4.08 mmol) according to the same procedure as 13a, from
12d (1.30 g, 4.54 mmol) and 2,4-dichloro-5-nitropyrimidine (970 mg,
5.00 mmol). HRMS (ESI +ve): found [M]+ 443.0118,
[C16H17BrClN4O4]
+ requires 443.0122; [α]D
22.0: +12.0 (c 1.0,
MeOH); δH (500 MHz, CDCl3): 8.64 (s, 1H), 7.45 (s, 1H), 7.41
(d, J = 7.8 Hz, 1H), 7.23 (d, J = 7.8 Hz, 1H), 7.17−7.13 (m, 1H),
4.75 (d, J = 15.8 Hz, 1H), 4.73−4.68 (m, 1H), 4.59 (d, J = 15.8 Hz,
1H), 3.82 (s, 3H), 2.32−2.23 (m, 1H), 2.10−2.00 (m, 1H), 1.07 (t, J
= 7.4 Hz, 3H).
(R)-Methyl 2-((2-Chloro-5-nitropyrimidin-4-yl)((3-methylthio-
phen-2-yl)methyl)amino)butanoate (13e). 13e was synthesized in
90% yield (yellow solid, 1.18 g, 3.07 mmol) according to the same
procedure as 13d, from 12e (770 mg, 3.39 mmol) and 2,4-dichloro-5-
nitropyrimidine (723 mg, 3.72 mmol). HRMS (ESI +ve): found [M]+
385.0732, [C15H17ClN4O4S]
+ requires 385.0732; [α]D
22.1: +4.85 (c 1.0,
MeOH); δH (500 MHz, CDCl3): 8.65 (s, 1H), 7.15 (d, J = 5.2 Hz,
1H), 6.70 (d, J = 5.2 Hz, H2), 4.92 (dd, J = 5.4, 4.1 Hz, 1H), 4.75 (s,
2H), 3.80 (s, 3H), 2.30−2.20 (m, 1H), 2.16 (s, 3H), 2.07−2.00 (m,
1H), 1.09 (t, J = 7.4 Hz, 3H).
(R)-Methyl 2-((2-Chloro-5-nitropyrimidin-4-yl)((4-methylthio-
phen-2-yl)methyl)amino)butanoate (13f). 13f was synthesized in
81% yield (yellow solid, 2.32 g, 6.03 mmol) according to the same
procedure as 13d, from 12f (1.70 g, 7.48 mmol) and 2,4-dichloro-5-
nitropyrimidine (1.60 g, 8.23 mmol). HRMS (ESI +ve): found [M]+
385.0738, [C15H17ClN4O4S]
+ requires 385.0732; [α]D
22.5: +5.54 (c 1.0,
MeOH); δH (500 MHz, CDCl3): 8.70 (s, 1H), 6.82−6.81 (m, 1H),
6.71 (s, 1H), 4.95−4.80 (m, 3H), 3.82 (s, 3H), 2.32−2.22 (m, 1H),
2.18 (s, 3H), 2.09−2.00 (m, 1H), 1.07 (t, J = 7.4 Hz, 3H).
(R)-Methyl 2-((2-Chloro-5-nitropyrimidin-4-yl)((5-methylthio-
phen-2-yl)methyl)amino)butanoate (13g). 13g was synthesized in
86% yield (yellow gum, 1.30 g, 3.38 mmol) according to the same
procedure as 13d, from 12g (892 mg, 3.92 mmol) and 2,4-dichloro-5-
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nitropyrimidine (837 mg, 4.31 mmol). HRMS (ESI +ve): found [M]+
385.0732, [C15H17ClN4O4S]
+ requires 385.0732; [α]D
22.4: −2.78 (c
1.0, MeOH); δH (500 MHz, CDCl3): 8.68 (s, 1H), 6.67 (d, J = 2.5
Hz, 1H), 6.52 (d, J = 2.5 Hz, H2), 4.98−4.93 (m, 1H), 4.84 (d, J =
15.9 Hz, 1H), 4.81 (d, J = 15.9 Hz, 1H), 3.81 (s, 3H), 2.38 (s, 3H),
2.31−2.21 (m, 1H), 2.08−2.00 (m, 1H), 1.06 (t, J = 7.4 Hz, 3H).
(R)-2-Chloro-8-cyclopentyl-7-ethyl-7,8-dihydropteridin-6(5H)-
one (14a). A mixture of 13a (1.00 g, 2.92 mmol) in AcOH (0.4 M)
was heated to 100 °C. Iron powder (196 mg, 3.5 mmol) was added
batchwise, and the reaction was stirred for 6 h. Upon completion, the
mixture was ﬁltered through celite, washed with MeOH, and
concentrated in vacuo. The residue was puriﬁed by Biotage column
chromatography (cHex/EtOAc, 0−40%) to aﬀord the title compound
14a as a yellow solid (345 mg, 1.23 mmol, 25%). HRMS (ESI +ve):
found [M]+ 281.1163, [C13H18ClN4O]
+ requires 281.1169; [α]D
22.1:
−96.2 (c 1.0, MeOH); δH (500 MHz, CDCl3): 9.39 (s, 1H), 7.68 (s,
1H), 4.37−4.29 (m, 1H), 4.21 (dd, J = 7.4, 3.6 Hz, 1H), 2.11−2.05
(m, 1H), 2.00−1.74 (m, 7H), 1.70−1.61 (m, 2H), 0.96 (t, J = 7.6 Hz,
3H).
(S)-2-Chloro-8-cyclopentyl-7-ethyl-7,8-dihydropteridin-6(5H)-
one (14b). 14b was synthesized in 28% yield (yellow solid, 186 mg,
0.66 mmol) according to the same procedure as 14d, from 13b (815
mg, 2.38 mmol). HRMS (ESI +ve): found [M]+ 281.1163,
[C13H18ClN4O]
+ requires 281.1169; [α]D
22.1: +95.3 (c 1.0, MeOH);
δH (500 MHz, CDCl3): 9.67 (s, 1H), 7.70 (s, 1H), 4.32 (quin, J = 8.4
Hz, 1H), 4.21 (dd, J = 7.3, 3.5 Hz, 1H), 2.12−2.04 (m, 1H), 2.00−
1.73 (m, 7H), 1.70−1.60 (m, 2H), 0.94 (t, J = 7.6 Hz, 3H).
2-Chloro-8-cyclopentyl-7,8-dihydropteridin-6(5H)-one (14c). 14c
was synthesized in 31% yield (orange solid, 101 mg, 0.40 mmol)
according to the same procedure as 14d, from 13c (410 mg, 1.30
mmol). HRMS (ESI +ve): found [M]+ 281.1163, [C13H18ClN4O]
+
requires 281.1169; [α]D
22.1: +95.3 (c 1.0, MeOH); δH (500 MHz,
CDCl3): 7.98 (s, 1H), 7.60 (s, 1H), 6.15 (quin, J = 8.4 Hz, 1H), 4.11
(s, 2H), 1.98−1.89 (m, 2H), 1.80−1.57 (m, 6H).
(R)-2-Chloro-8-(3-bromobenzyl)-7-ethyl-7,8-dihydropteridin-
6(5H)-one (14d). 14d was synthesized in 42% yield (orange solid, 387
mg, 1.01 mmol) according to the same procedure as 14a, from 13d
(1.80 g, 4.06 mmol). HRMS (ESI +ve): found [M]+ 383.0078,
[C15H15BrClN4O]
+ requires 383.0091; [α]D
22.0: −18.0 (c 1.0, MeOH);
δH (500 MHz, CDCl3): 9.33 (s, 1H), 7.71 (s, 1H), 7.48−7.45 (m,
1H), 7.45 (s, 1H), 7.26−7.23 (m, 2H), 5.62 (d, J = 15.1, 1H), 4.16−
4.12 (m, 1H), 4.08 (d, J = 15.1, 1H), 2.05−1.97 (m, 1H), 1.96−1.86
(m, 1H), 0.91 (t, J = 7.4 Hz, 3H).
(R)-2-Chloro-7-ethyl-8-((3-methylthiophen-2-yl)methyl)-7,8-di-
hydropteridin-6(5H)-one (14e). 14e was synthesized in 47% yield
(orange solid, 380 mg, 1.17 mmol) according to the same procedure
as 14d, from 13e (960 mg, 2.49 mmol). HRMS (ESI +ve): found
[M]+ 323.0724, [C14H15ClN4OS]
+ requires 323.0728; [α]D
22.2: −11.1
(c 1.0, MeOH); δH (500 MHz, CDCl3): 8.70 (s, 1H), 7.65 (s, 1H),
6.86 (d, J = 3.3 Hz, 1H), 6.63−6.61 (m, 1H), 5.55 (d, J = 15.5, 1H),
4.33−4.29 (m, 2H), 2.46 (s, 3H), 2.07−1.88 (m, 2H), 0.90 (t, J = 7.4
Hz, 3H).
(R)-2-Chloro-7-ethyl-8-((4-methylthiophen-2-yl)methyl)-7,8-di-
hydropteridin-6(5H)-one (14f). 14f was synthesized in 42% yield
(orange solid, 300 mg, 0.93 mmol) according to the same procedure
as 14d, from 13f (860 mg, 2.23 mmol). HRMS (ESI +ve): found
[M]+ 323.0728, [C14H15ClN4OS]
+ requires 323.0728; [α]D
22.8: −18.0
(c 1.0, MeOH); δH (500 MHz, CDCl3): 7.73 (s, 1H), 6.86 (s, 1H),
6.83 (d, J = 1.0 Hz, 1H), 5.58 (d, J = 15.5 Hz, 1H), 4.32−4.28 (m,
2H), 2.23 (s, 3H), 2.07−1.99 (m, 1H), 1.97−1.86 (m, 1H), 0.89 (t, J
= 7.4 Hz, 3H).
(R)-2-Chloro-7-ethyl-8-((5-methylthiophen-2-yl)methyl)-7,8-di-
hydropteridin-6(5H)-one (14g). 14g was synthesized in 18% yield
(orange solid, 200 mg, 0.62 mmol) according to the same procedure
as 14d, from 13g (1.30 g, 3.38 mmol). HRMS (ESI +ve): found [M]+
323.0727, [C14H15ClN4OS]
+ requires 323.0728; [α]D
22.5: +18.7 (c 1.0,
MeOH); δH (500 MHz, CDCl3): 9.20 (s, 1H), 7.69 (s, 1H), 7.18 (d, J
= 5.2 Hz, 1H), 6.83 (d, J = 5.2 Hz, 1H), 5.64 (d, J = 15.5 Hz, 1H),
4.29 (d, J = 15.5 Hz, 1H), 4.24 (dd, J = 6.3, 3.5 Hz, 1H), 2.26 (s, 3H),
2.05−1.99 (m, 1H), 1.98−1.87 (m, 1H), 0.92 (t, J = 7.6 Hz, 3H).
(R)-2-Chloro-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteri-
din-6(5H)-one (15a). 14a (200 mg, 0.72 mmol) was dissolved in
DMF (0.1 M), methyl iodide (58 μL, 0.93 mmol) was added, and the
mixture was cooled to −10 °C. NaH (22 mg, 0.93 mmol) was added,
and the reaction was stirred for 16 h. Upon completion, ice was added
and the aqueous phase was extracted with EtOAc (×3). The
combined organic phases were washed with water, dried over MgSO4,
ﬁltered, and concentrated in vacuo. The residue was puriﬁed by
Biotage column chromatography (cHex/EtOAc, 0−20%) to aﬀord
the title compound 15a as a white solid (200 mg, 0.68 mmol, 71%).
HRMS (ESI +ve): found [M]+ 295.1321, [C14H20ClN4O]
+ requires
295.1326; [α]D
21.4: −88.3 (c 1.0, MeOH); δH (500 MHz, CDCl3): 7.62
(s, 1H), 4.41−4.29 (m, 1H), 4.25 (dd, J = 7.6, 3.5 Hz, 1H), 3.33 (s,
3H), 2.12−2.04 (m, 1H), 2.02−1.58 (m, 9H), 0.86 (t, J = 7.4 Hz,
3H).
(S)-2-Chloro-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteri-
din-6(5H)-one (15b). 15b was synthesized in 95% yield (white solid,
180 mg, 0.61 mmol) according to the same procedure as 15d, from
14b (180 mg, 0.64 mmol) and methyl iodide (52 μL, 0.83 mmol).
HRMS (ESI +ve): found [M]+ 295.1321, [C14H20ClN4O]
+ requires
295.1326; [α]D
21.5: +93.5 (c 1.0, MeOH); δH (500 MHz, CDCl3): 7.65
(s, 1H), 4.37−4.28 (m, 1H), 4.23 (dd, J = 7.6, 3.8 Hz, 1H), 3.31 (s,
3H), 2.10−2.02 (m, 1H), 2.00−1.58 (m, 9H), 0.85 (t, J = 7.6 Hz,
3H).
2-Chloro-8-cyclopentyl-5-methyl-7,8-dihydropteridin-6(5H)-one
(15c). 15c was synthesized in 59% yield (white solid, 53 mg, 0.20
mmol) according to the same procedure as 15d, from 14c (85 mg,
0.37 mmol) and methyl iodide (27 μL, 0.43 mmol). HRMS (ESI
+ve): found [M]+ 267.0995, [C12H15ClN4O]
+ requires 267.1007; δH
(500 MHz, CDCl3): 7.67 (s, 1H), 5.14 (quin, J = 8.4 Hz, 1H), 4.13
(s, 2H), 4.37−4.28 (m, 1H), 3.33 (s, 3H), 1.97−1.91 (m, 2H), 1.81−
1.65 (m, 4H), 1.64−1.56 (m, 2H).
(R)-8-(3-Bromobenzyl)-2-chloro-7-ethyl-5-methyl-7,8-dihydrop-
teridin-6(5H)-one (15d). 15d was synthesized in 71% yield (yellow
solid, 200 mg, 0.51 mmol) according to the same procedure as 15a,
from 14d (270 mg, 0.71 mmol) and methyl iodide (58 μL, 0.92
mmol). HRMS (ESI +ve): found [M]+ 395.0269, [C16H17BrClN4O]
+
requires 395.0274; [α]D
22.1: +15.2 (c 1.0, MeOH); δH (500 MHz,
CDCl3): 7.73 (s, 1H), 7.48−7.44 (m, 2H), 7.25−7.22 (m, 2H), 5.62
(d, J = 15.1 Hz, 1H), 4.17 (dd, J = 6.3, 3.5 Hz, 1H), 4.09 (d, J = 15.1
Hz, 1H), 3.35 (s, 3H), 2.02−1.93 (m, 1H), 1.90−1.80 (m, 1H), 0.84
(t, J = 7.4 Hz, 3H).
(R)-2-Chloro-7-ethyl-5-methyl-8-(3-methylthiophen-2-yl)-7,8-di-
hydropteridin-6(5H)-one (15e). 15e was synthesized in 48% yield
(yellow solid, 186 mg, 0.55 mmol) according to the same procedure
as 15d, from 14e (370 mg, 1.15 mmol) and methyl iodide (72 μL,
1.15 mmol). HRMS (ESI +ve): found [M]+ 337.0901,
[C15H17ClN4OS]
+ requires 337.0884; [α]D
23.3: +6.9 (c 1.0, MeOH);
δH (500 MHz, CDCl3): 7.69 (s, 1H), 7.17 (d, J = 5.4 Hz, 1H), 6.83
(d, J = 5.4 Hz, 1H), 5.61 (d, J = 15.3 Hz, 1H), 4.29 (d, J = 15.3 Hz,
1H), 4.27 (dd, J = 6.6, 3.5 Hz, 1H), 3.32 (s, 3H), 2.25 (s, 3H), 2.03−
1.93 (m, 1H), 1.91−1.81 (m, 1H), 0.84 (t, J = 7.6 Hz, 3H).
(R)-2-Chloro-7-ethyl-5-methyl-8-(4-methylthiophen-2-yl)-7,8-di-
hydropteridin-6(5H)-one (15f). 15f was synthesized in 53% yield
(yellow oil, 260 mg, 0.77 mmol) according to the same procedure as
15d, from 14f (470 mg, 1.46 mmol) and methyl iodide (19 μL, 1.90
mmol). HRMS (ESI +ve): found [M]+ 337.0881, [C15H17ClN4OS]
+
requires 337.0884; [α]D
23.3: +4.9 (c 1.0, MeOH); δH (500 MHz,
CDCl3): 7.69 (s, 1H), 6.86 (s, 1H), 6.82 (s, 1H), 5.56 (d, J = 15.5 Hz,
1H), 4.33−4.29 (2H, m), 3.31 (s, 3H), 2.22 (s, 3H), 2.03−1.95 (m,
1H), 1.91−1.84 (m, 1H), 0.81 (t, J = 7.4 Hz, 3H).
(R)-2-Chloro-7-ethyl-5-methyl-8-(5-methylthiophen-2-yl)-7,8-di-
hydropteridin-6(5H)-one (15g). 15g was synthesized in 53% yield
(yellow solid, 110 mg, 0.33 mmol) according to the same procedure
as 15d, from 14g (200 mg, 0.62 mmol) and methyl iodide (39 μL,
0.62 mmol). HRMS (ESI +ve): found [M]+ 337.0866,
[C15H17ClN4OS]
+ requires 337.0884; [α]D
23.5: +1.7 (c 1.0, MeOH);
δH (500 MHz, CDCl3): 7.69 (s, 1H), 6.85 (d, J = 3.5 Hz, 1H), 6.61−
6.59 (m, 1H), 5.53 (d, J = 15.5 Hz, 1H), 4.33−4.29 (2H, m), 3.32 (s,
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b01947
J. Med. Chem. XXXX, XXX, XXX−XXX
N
3H), 2.45 (s, 3H), 2.04−1.95 (m, 1H), 1.91−1.83 (m, 1H), 0.82 (t, J
= 7.4 Hz, 3H).
(R)-8-Cyclopentyl-7-ethyl-2-((2-methoxy-4-(1-methylpiperidin-4-
yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (16a).
To 15a (25 mg, 80 μmol) and 10b (18 mg, 80 μmol) in a solvent
mixture of dioxane/EtOH/H2O (1:1:1, 0.1 M) was added conc. HCl
(24 μL, 110 μmol). The reaction was stirred at 120 °C for 48 h. Upon
completion, the reaction mixture was partitioned between EtOAc and
NaOH (1 M) and the aqueous layer was further extracted with EtOAc
(×2). The organic phase was combined, dried over MgSO4, and
concentrated in vacuo. The residue was puriﬁed by Biotage column
chromatography (DCM/20% amm. MeOH, 0−40%) and reverse
phase column chromatography (water/MeOH, 0−100%) to aﬀord
16a as a yellow solid (9.0 mg, 19 μmol, 22%). HRMS (ESI +ve):
found [M]+ 479.3101, [C27H38N6O2]
+ requires 479.3129; [α]D
21.8:
−9.1 (c 1.0, MeOH); δH (500 MHz, CDCl3): 8.20 (d, J = 8.2 Hz,
1H), 7.88 (s, 1H), 7.61 (s, 1H), 6.80 (dd, J = 8.2, 1.9 Hz, 1H), 6.75
(d, J = 1.9 Hz, 1H), 4.42 (quin, J = 8.0 Hz, 1H), 4.21 (dd, J = 7.7. 3.6
Hz, 1H), 3.90 (s, 3H), 3.59 (d, J = 10.7 Hz, 2H), 3.31 (s, 3H), 2.75
(s, 3H), 2.77−2.67 (m, 3H), 2.27 (q, J = 12.5 Hz, 2H), 2.14−1.92
(m, 4H), 1.92−1.60 (m, 8H), 0.87 (t, J = 7.6 Hz, 3H).
(R)-4-((8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahy-
dropteridin-2-yl)amino)-3-isobutoxy-N-(1-methylpiperidin-4-yl)-
benzamide (16b). 16b was synthesized in 28% yield (white solid, 7.0
mg, 12 μmol) according to the same procedure as 16h, from 15a (13
mg, 44 μmol) and 5a (14 mg, 44 μmol). HRMS (ESI +ve): found
[M]+ 564.3652, [C31H45N7O3]
+ requires 564.3657; [α]D
20.8: −31.2 (c
1.0, MeOH); δH (500 MHz, CDCl3): 8.55 (d, J = 8.4 Hz, 1H), 7.68
(s, 1H), 7.67 (s, 1H), 7.40 (d, J = 1.6 Hz, 1H), 7.22 (dd, J = 8.4, 1.6
Hz, 1H), 6.50 (d, J = 6.9 Hz, 1H), 4.40−4.32 (m, 1H), 4.23 (dd, J =
7.4, 3.3 Hz, 1H), 4.22−4.17 (m, 1H), 3.90 (d, J = 6.3 Hz, 2H), 3.41
(d, J = 10.4 Hz, 2H), 3.33 (s, 3H), 2.68 (t, J = 8.0 Hz, 2H), 2.33 (s,
3H), 2.26−1.65 (m, 15H), 1.09 (d, J = 6.6 Hz, 6H), 0.87 (t, J = 7.4
Hz, 3H).
(R)-4-((8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahy-
dropteridin-2-yl)amino)-3-ethoxy-N-(1-methylpiperidin-4-yl)-
benzamide (16c). 16c was synthesized in 24% yield (white solid, 13
mg, 24 μmol) according to the same procedure as 16h, from 15a (30
mg, 102 μmol) and 5b (28 mg, 102 μmol). HRMS (ESI +ve): found
[M]+ 536.3345, [C29H41N7O3]
+ requires 536.3349; [α]D
21.8: −62.3 (c
1.0, MeOH); δH (500 MHz, CDCl3): 8.55 (d, J = 8.2 Hz, 1H), 7.73
(s, 1H), 7.68 (s, 1H), 7.41 (d, J = 1.9 Hz, 1H), 7.35 (dd, J = 8.3, 1.9
Hz, 1H), 6.56 (s, 1H), 4.52−4.44 (m, 1H), 4.28−4.18 (m, 4H), 3.50
(d, J = 10.4 Hz, 2H), 3.34 (s, 3H), 2.72−2.64 (m, 2H), 2.74 (s, 3H),
2.20−1.97 (m, 6H), 1.93−1.68 (m, 8H), 1.51 (t, J = 6.9 Hz, 3H),
0.88 (t, J = 7.4 Hz, 3H).
(S)-4-((8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahy-
dropteridin-2-yl)amino)-3-ethoxy-N-(1-methylpiperidin-4-yl)-
benzamide (16d). 16d was synthesized in 42% yield (white solid, 23
mg, 43 μmol) according to the same procedure as 16h, from 15b (30
mg, 102 μmol) and 5b (28 mg, 102 μmol). HRMS (ESI +ve): found
[M]+ 536.3329, [C29H41N7O3]
+ requires 536.3349; [α]D
21.8: +51.9 (c
1.0, MeOH); δH (500 MHz, CDCl3): 8.55 (d, J = 8.2 Hz, 1H), 7.89
(s, 1H), 7.67 (s, 1H), 7.45 (d, J = 1.9 Hz, 1H), 7.35 (dd, J = 8.3, 1.9
Hz, 1H), 6.56 (s, 1H), 4.52−4.44 (m, 1H), 4.33−4.23 (m, 2H), 4.20
(q, J = 6.9 Hz, 2H), 3.50 (d, J = 10.4 Hz, 2H), 3.33 (s, 3H), 2.72−
2.64 (m, 2H), 2.78 (s, 3H), 2.20−1.97 (m, 6H), 1.93−1.68 (m, 8H),
1.50 (t, J = 6.9 Hz, 3H), 0.88 (t, J = 7.6 Hz, 3H).
4-((8-Cyclopentyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-
yl)amino)-3-ethoxy-N-(1-methylpiperidin-4-yl)benzamide (16e).
16e was synthesized in 6.6% yield (white solid, 2.0 mg, 3.9 μmol)
according to the same procedure as 16h, from 15c (16 mg, 60 μmol)
and 5b (16 mg, 57 μmol). HRMS (ESI +ve): found [M]+ 508.3028,
[C29H41N7O3]
+ requires 508.3031; δH (500 MHz, CDCl3): 8.53 (d, J
= 8.4 Hz, 1H), 7.69 (s, 1H), 7.63 (s, 1H), 7.41 (d, J = 1.8 Hz, 1H),
7.23 (dd, J = 8.4, 1.8 Hz, 1H), 5.91 (s, 1H), 5.16 (quin, J = 8.1 Hz,
H3), 4.22 (q, J = 7.6 Hz, 2H), 4.09 (s, 2H), 4.03−3.94 (m, 1H), 3.33
(s, 3H), 2.88−2.80 (m, 2H), 2.32 (s, 3H), 2.20−2.15 (m, 2H), 2.06
(m, 2H), 2.01−1.93 (m, 2H), 1.84−1.58 (m, 8H), 1.52 (t, J = 7.6 Hz,
3H).
(R)-4-((8-(3-Bromobenzyl)-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetra-
hydropteridin-2-yl)amino)-3-ethoxy-N-(1-methylpiperidin-4-yl)-
benzamide (16f). 16f was synthesized in 53% yield (white solid, 55
mg, 86 μmol) according to the same procedure as 16h, from 15d (65
mg, 164 μmol) and 5b (46 mg, 164 μmol). HRMS (ESI +ve): found
[M]+ 622.2302, [C31H38BrN7O3]
+ requires 636.2298; [α]D
22.1: +5.1 (c
1.0, MeOH); δH (500 MHz, CDCl3): 8.23 (d, J = 8.5 Hz, 1H), 7.74
(s, 1H), 7.63 (s, 1H), 7.50 (t, J = 1.6 Hz, 1H), 7.44 (dt, J = 7.6, 1.6
Hz, 1H), 7.42 (d, J = 1.9 Hz, 1H), 7.28−7.20 (m, 2H), 7.14 (dd, J =
8.5, 1.9 Hz, 1H), 5.96 (d, J = 7.9 Hz, 1H), 5.51 (d, J = 15.8 Hz, 1H),
4.23−4.16 (m, 4H), 4.04−3.94 (m, 1H), 3.38 (s, 3H), 2.76−2.67 (m,
2H), 2.31 (s, 3H), 2.17 (t, J = 10.9 Hz, 2H), 2.09−2.01 (m, 2H),
2.00−1.93 (m, 1H), 1.89−1.80 (m, 1H), 1.63−1.58 (m, 2H) 1.49 (t, J
= 7.1 Hz, 3H), 0.87 (t, J = 7.4 Hz, 3H).
(R)-4-((8-Benzyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteri-
din-2-yl)amino)-3-ethoxy-N-(1-methylpiperidin-4-yl)benzamide
(16g). 16g was synthesized in 46% yield (pale yellow solid, 4.0 mg,
7.2 μmol) according to the same procedure as 16i, from 16f (10 mg,
16 μmol). HRMS (ESI +ve): found [M]+ 558.3161, [C31H39N7O3]
+
requires 558.3193; [α]D
21.9: −9.7 (c 1.0, MeOH); δH (500 MHz,
CDCl3): 8.45 (d, J = 8.5 Hz, 1H), 7.75 (s, 1H), 7.73 (s, 1H), 7.42 (d,
J = 1.6 Hz, 1H), 7.40−7.29 (m, 6H), 6.61 (d, J = 8.2 Hz, 1H), 5.66
(d, J = 15.1 Hz, 1H), 4.28−4.19 (m, 4H), 4.18 (dd, J = 6.3, 3.5 Hz,
1H), 3.48 (d, J = 11.7 Hz, 2H), 3.37 (s, 3H), 2.80−2.72 (m, 2H),
2.73 (s, 3H), 2.20−2.12 (m, 4H), 2.01−1.92 (m, 1H), 1.91−1.82 (m,
1H), 1.51 (t, J = 6.9 Hz, 3H), 0.87 (t, J = 7.9 Hz, 3H).
(R)-8-(3-Bromobenzyl)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)-
phenyl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one
(16h). 16h was synthesized in 29% yield (white solid, 30 mg, 51
μmol) according to the same procedure as 16a, from 15d (69 mg, 174
μmol) and 10a (39 mg, 166 μmol). HRMS (ESI +ve): found [M]+
593.2209, [C30H38BrN6O2]
+ requires 593.2234; [α]D
23.7: +1.7 (c 1.0,
MeOH); δH (500 MHz, CDCl3): 8.13 (s, 1H), 7.96 (d, J = 8.2 Hz,
1H), 7.68 (s, 1H), 7.46−7.42 (m, 2H), 7.23−7.20 (m, 2H), 6.74−
6.70 (m, 2H), 5.51 (d, J = 15.5 Hz, 1H), 4.19−4.13 (m, 2H), 4.11 (q,
J = 6.9 Hz, 2H), 3.67−3.63 (m, 2H), 3.35 (s, 3H), 2.85−2.75 (m,
2H), 2.82 (s, 3H), 2.70−2.61 (m, 1H), 2.28 (q, J = 12.3 Hz, 2H),
2.05−1.94 (m, 3H), 1.90−1.80 (m, 1H), 1.47 (t, J = 6.9 Hz, 3H),
0.85 (t, J = 7.6 Hz, 3H).
(R)-8-Benzyl-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)-
amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one (16i). A
solution of 16h (14 mg, 24 μmol) and 10% Pd·C (1.5 mg, 14
μmol) in MeOH (0.01 M) was stirred at rt under a hydrogen
atmosphere (1 atm) for 1 h. The mixture was ﬁltered through celite
and washed with MeOH. The solvent was removed in vacuo, and the
residue was puriﬁed by reverse phase column chromatography
(water/MeOH, 0−100%) to give the title compound 16i as a white
solid (5.0 mg, 9.7 μmol, 41%). HRMS (ESI +ve): found [M]+
515.3114, [C30H40N6O2]
+ requires 515.3129; [α]D
23.7: +24.2 (c 1.0,
MeOH); δH (500 MHz, CDCl3): 8.22 (d, J = 8.8 Hz, 1H), 7.68 (s,
1H), 7.58 (s, 1H), 7.37−7.29 (m, 5H), 6.72 (d, J = 1.6 Hz, 1H), 6.70
(dd, J = 8.2, 1.6 Hz, 1H), 5.62 (d, J = 15.1 Hz, 1H), 4.18−4.15 (m,
3H), 4.11 (q, J = 7.2 Hz, 2H), 3.64 (d, J = 10.4 Hz, 2H), 3.34 (s, 3H),
2.73 (s, 3H), 2.73−2.58 (m, 3H), 2.25−2.15 (m, 2H), 2.02−1.92 (m,
3H), 1.90−1.81 (m, 1H), 1.48 (t, J = 6.9 Hz, 3H), 0.85 (t, J = 7.4 Hz,
3H).
(R)-2-((2-Ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-
ethyl-5-methyl-8-((3-methylthiophen-2-yl)methyl)-7,8-dihydropter-
idin-6(5H)-one (16j). 16j was synthesized in 9.4% yield (yellow solid,
6.0 mg, 11 μmol) according to the same procedure as 16h, from 15e
(40 mg, 120 μmol) and 10a (26 mg, 110 μmol). HRMS (ESI +ve):
found [M]+ 535.2828, [C29H39N6O2S]
+ requires 535.2850; [α]D
23.5:
+7.6 (c 1.0, MeOH); δH (500 MHz, CDCl3): 8.31 (d, J = 8.2 Hz,
1H), 7.67 (s, 1H), 7.64 (s, 1H), 7.15 (d, J = 5.0 Hz, 1H), 6.83 (d, J =
5.0 Hz, 1H), 6.78 (dd, J = 8.2, 1.6 Hz, 1H), 6.73 (d, J = 1.6 Hz, 1H),
5.63 (d, J = 15.1 Hz, 1H), 4.33 (d, J = 15.1 Hz, 1H), 4.19 (dd, J = 6.5,
3.6 Hz, 1H), 4.13 (q, J = 6.9 Hz, 2H), 3.57 (d, J = 9.1 Hz, 2H), 3.32
(s, 3H), 2.76−2.60 (m, 6H), 2.25 (s, 3H), 2.24−2.15 (m, 2H), 2.02−
1.91 (m, 3H), 1.88−1.79 (m, 1H), 1.49 (t, J = 6.9 Hz, 3H), 0.85 (t, J
= 7.4 Hz, 3H).
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(R)-2-((2-Ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-
ethyl-5-methyl-8-((4-methylthiophen-2-yl)methyl)-7,8-dihydropter-
idin-6(5H)-one (16k). 16k was synthesized in 23% yield (yellow solid,
20 mg, 37 μmol) according to the same procedure as 16h, from 15f
(55 mg, 163 μmol) and 10a (36 mg, 155 μmol). HRMS (ESI +ve):
found [M]+ 535.2835, [C29H39N6O2S]
+ requires 535.2850; [α]D
22.6:
+7.6 (c 1.0, MeOH); δH (500 MHz, CDCl3): 8.34 (d, J = 8.2 Hz,
1H), 7.67 (s, 1H), 7.45 (s, 1H), 7.14 (d, J = 1.3 Hz, 1H), 6.85 (s,
1H), 6.82−6.76 (m, 3H), 5.61 (d, J = 15.5 Hz, 1H), 4.34 (d, J = 15.5
Hz, 1H), 4.25 (dd, J = 6.3, 3.5 Hz 1H), 4.11 (q, J = 6.9 Hz, 2H),
3.35−3.29 (m, 5H), 2.60 (s, 3H), 2.58−2.46 (m, 3H), 2.22 (s, 3H),
2.20−2.12 (m, 2H), 2.00−1.92 (m, 3H), 1.89−1.80 (m, 1H), 1.48 (t,
J = 6.9 Hz, 3H), 0.85 (t, J = 7.6 Hz, 3H).
(R)-2-((2-Ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-
ethyl-5-methyl-8-((5-methylthiophen-2-yl)methyl)-7,8-dihydropter-
idin-6(5H)-one (16l). 16l was synthesized in 25% yield (yellow oil, 18
mg, 34 μmol) according to the same procedure as 16h, from 15g (45
mg, 134 μmol) and 10a (30 mg, 127 μmol). HRMS (ESI +ve): found
[M]+ 535.2833, [C29H39N6O2S]
+ requires 535.2850; [α]D
23.6: +11.1 (c
1.0, MeOH); δH (500 MHz, CDCl3): 8.34 (d, J = 8.2 Hz, 1H), 7.67
(s, 1H), 7.63 (s, 1H), 6.83 (d, J = 3.2 Hz, 1H), 6.79 (dd, J = 8.2, 1.9
Hz, 1H), 6.75 (d, J = 1.8 Hz, 1H), 6.60 (d, J = 3.2 Hz, 1H), 5.57 (d, J
= 15.5 Hz, 1H), 4.43 (d, J = 15.5 Hz, 1H), 4.26 (dd, J = 6.2, 3.6 Hz,
1H), 4.14 (q, J = 6.9 Hz, 2H), 3.57 (d, J = 10.1 Hz, 2H), 3.32 (s, 3H),
2.73 (s, 3H), 2.73−2.61 (m, 3H), 2.44 (s, 3H), 2.25−2.15 (m, 2H),
2.02−1.92 (m, 3H), 1.89−1.80 (m, 1H), 1.60 (t, J = 6.9 Hz, 3H),
0.84 (t, J = 7.4 Hz, 3H).
(R)-Methyl 2-((2,4-Dimethoxybenzyl)amino)butanoate (17). 17
was synthesized in 97% yield (yellow oil, 27.0 g, 101 mmol) according
to the same procedure as 12d, from (R)-methyl 2-aminobutanoate
11a (HCl salt, 16.0 g, 104 mmol) and 2,4-dimethoxybenzaldehye
(17.3 g, 101 mmol). HRMS (ESI +ve): found [M]+ 268.1541,
[C14H21NO4]
+ requires 268.1543; [α]D
23.9: +11.8 (c 1.0, MeOH); δH
(500 MHz, CDCl3): 7.13 (d, J = 7.9 Hz, 1H), 6.45−6.41 (m, 2H),
3.81 (s, 3H), 3.80 (s, 3H), 3.71 (d, J = 13.2 Hz, 1H), 3.67−3.74 (m,
4H), 3.21 (t, J = 6.5 Hz, 1H), 1.73−1.63 (m, 2H), 0.91 (t, J = 7.4 Hz,
3H).
(R ) -Methy l 2- ( (2-Chloro-5-n i t ropyr imid in-4-y l ) (2 ,4-
dimethoxybenzyl)amino)butanoate (18). 18 was synthesized in
78% yield (yellow gum, 33.4 g, 78.6 mmol) according to the same
procedure as 13d, from 17 (27.0 g, 101 mmol) and 2,4-dichloro-5-
nitropyrimidine 15 (21.6 g, 111 mmol). HRMS (ESI +ve): found
[M]+ 425.1211, [C18H21ClN4O6]
+ requires 425.1222; [α]D
23.7: −6.9 (c
1.0, MeOH); δH (500 MHz, CDCl3): 8.65 (s, 1H), 7.04 (d, J = 8.2
Hz, 1H), 6.40−6.37 (m, 2H), 4.47−4.43 (m, 2H), 4.40 (d, J = 16.1
Hz, 1H), 3.79 (s, 3H), 3.71 (s, 3H), 3.62 (s, 3H), 2.28−2.18 (m, 1H),
2.07−1.99 (m, 1H), 1.05 (t, J = 7.4 Hz, 3H).
(R)-2-Chloro-8-(2,4-dimethoxybenzyl)-7-ethyl-7,8-dihydropteri-
din-6(5H)-one (19). A solution of 18 (13.0 g, 30.6 mmol), 10% Pt·C
(597 mg, 3.06 mmol), and VO(acac)2 (650 mg, 2.45 mmol) in THF
(0.3 M) was stirred at rt under a hydrogen atmosphere (1 atm) for 48
h. The mixture was ﬁltered through celite, and the solvent was
removed in vacuo to give 19 as a brown solid (11.0 g, 30.3 mmol,
98%). HRMS (ESI +ve): found [M]+ 363.1198, [C17H19ClN4O3]
+
requires 363.1218; [α]D
23.4: +15.2 (c 1.0, MeOH); δH (500 MHz,
CDCl3): 9.72 (1H), 7.65 (s, 1H), 7.30 (d, J = 9.1 Hz, 1H), 6.47−6.45
(m, 2H), 5.35 (d, J = 14.7 Hz, 2H), 4.28 (dd, J = 5.4, 4.4 Hz, 1H),
4.20 (d, J = 14.7 Hz, 1H), 3.80 (s, 6H), 2.03−1.94 (m, 2H), 0.94 (t, J
= 7.3 Hz, 3H).
(R)-2-Chloro-8-(2,4-dimethoxybenzyl)-7-ethyl-5-methyl-7,8-di-
hydropteridin-6(5H)-one (20). 20 was synthesized in 86% yield
(yellow oil, 9.66 g, 25.6 mmol) according to the same procedure as
15d, from 19 (10.8 g, 29.8 mmol) and methyl iodide (2.42 mL, 38.7
mmol). HRMS (ESI +ve): found [M]+ 377.1366, [C18H21ClN4O3]
+
requires 377.1375; [α]D
23.7: +35.3 (c 1.0, MeOH); δH (500 MHz,
CDCl3): 7.62 (s, 1H), 7.32 (d, J = 8.8 Hz, 1H), 6.47−6.45 (m, 2H),
5.34 (d, J = 14.5 Hz, 1H), 4.34 (dd, J = 6.3, 3.8 Hz, 1H), 4.20 (d, J =
14.7 Hz, 1H), 3.81 (s, 6H), 3.30 (s, 3H), 1.99−1.85 (m, 2H), 0.85 (t,
J = 7.9 Hz, 3H).
(R)-2-Chloro-7-5-methyl-7,8-dihydropteridin-6(5H)-one (21). A
solution of 20 (5.09 g, 13.5 mmol) in TFA (1.3 M) was stirred at
80 °C for 4 h. Upon completion, the reaction was concentrated in
vacuo to remove the majority of the TFA. The remaining TFA was
quenched with sat. NaHCO3 until pH 7−8 was reached and extracted
with DCM (×3). The organic layers were washed with brine, dried
over MgSO4, ﬁltered, and concentrated in vacuo. The residue was
puriﬁed by Biotage column chromatography (DCM/MeOH, 0−15%)
to give 21 as a brown solid (2.02 g, 8.91 mmol, 66%). HRMS (ESI
+ve): found [M]+ 227.0695, [C9H11ClN4O]
+ requires 227.0694;
[α]D
23.7: +35.3 (c 1.0, MeOH); δH (500 MHz, CDCl3): 7.73 (s, 1H),
6.39 (s, 1H), 4.34 (dd, J = 6.3, 4.7 Hz, 1H), 3.34 (s, 3H), 2.03−1.87
(m, 2H), 0.99 (t, J = 7.4 Hz, 3H).
(R)-2-Chloro-8-(3-chlorobenzyl)-7-ethyl-5-methyl-7,8-dihydrop-
teridin-6(5H)-one (22a). To a solution of 21 (50 mg, 0.22 mmol) in
DMF (0.2 M) was added 1-(bromomethyl)-3-chlorobenzene (36 μL,
0.28 mmol). The mixture was cooled to −10 °C, NaH (12 mg, 0.50
mmol) was added, and then the mixture was stirred at rt for 18 h.
Upon completion, ice was added and the reaction was partitioned
between EtOAc and water. The aqueous layer was further extracted
with EtOAc (×3). The combined organic phases were washed with
water (×2), dried over MgSO4, ﬁltered, and concentrated in vacuo.
The residue was puriﬁed by Biotage column chromatography (cHex/
EtOAc, 0−20%) to give 22a as an orange solid (51 mg, 0.15 mmol,
66%). HRMS (ESI +ve): found [M]+ 351.0775, [C16H16Cl2N4O]
+
requires 351.0774; [α]D
23.6: −1.4 (c 1.0, MeOH); δH (500 MHz,
CDCl3): 7.73 (s, 1H), 7.32−7.28 (m, 3H), 7.20−7.18 (m, 1H), 5.62
(d, J = 15.1 Hz, 1H), 4.17 (dd, J = 6.2, 3.2 Hz, 1H), 4.08 (d, J = 15.1
Hz, 1H), 3.35 (s, 3H), 2.00−1.81 (m, 3H), 0.84 (t, J = 7.6 Hz, 3H).
(R)-3-((2-Chloro-7-ethyl-5-methyl-6-oxo-6,7-dihydropteridin-
8(5H)-yl)methyl)benzonitrile (22b). 22b was synthesized in 37%
yield (white solid, 28 mg, 0.08 mmol) according to the same
procedure as 22a, from 21 (50 mg, 0.22 mmol) and 3-
(bromomethyl)benzonitrile (35 μL, 0.28 mmol). HRMS (ESI +ve):
found [M]+ 341.1112, [C17H16ClN5O]
+ requires 342.1116; [α]D
23.7:
−1.4 (c 1.0, MeOH); δH (500 MHz, CDCl3): 7.74 (s, 1H), 7.63−7.56
(m, 2H), 7.56 (d, J = 7.7 Hz, 1H), 7.47 (t, J = 7.7 Hz, 1H), 5.58 (d, J
= 15.5 Hz, 1H), 4.18 (d, J = 15.5 Hz, 1H), 4.15 (dd, J = 6.5, 3.6 Hz,
1H), 3.35 (s, 3H), 2.01−1.94 (m, 1H), 1.87−1.78 (m, 1H), 0.83 (t, J
= 7.6 Hz, 3H).
(R)-2-Chloro-7-ethyl-8-(3-methoxybenzyl)-5-methyl-7,8-dihy-
dropteridin-6(5H)-one (22c). 22c was synthesized in 65% yield
(colorless oil, 50 mg, 0.14 mmol) according to the same procedure as
22a, from 21 (50 mg, 0.22 mmol) and 3-methoxybenzyl bromide (39
μL, 0.28 mmol). HRMS (ESI +ve): found [M]+ 347.1269,
[C17H19ClN4O2]
+ requires 347.1269; [α]D
23.6: −9.7 (c 1.0, MeOH);
δH (500 MHz, CDCl3): 7.69 (s, 1H), 7.28−7.24 (m, 1H), 6.87−6.84
(m, 3H), 5.63 (d, J = 15.1 Hz, 1H), 4.19 (dd, J = 6.3, 3.5 Hz, 1H),
4.10 (d, J = 15.1 Hz, 1H), 3.79 (s, 3H), 3.35 (s, 3H), 2.00−1.93 (m,
1H), 1.93−1.81 (m, 1H), 0.82 (t, J = 7.6 Hz, 3H).
(R)-2-Chloro-8-(2-bromobenzyl)-7-ethyl-5-methyl-7,8-dihydrop-
teridin-6(5H)-one (22d). 22d was synthesized in 62% yield (orange
solid, 87 mg, 0.22 mmol) according to the same procedure as 22a,
from 21 (80 mg, 0.35 mmol) and 1-(bromomethyl)-2-chloro-benzene
(111 mg, 0.45 mmol). HRMS (ESI +ve): found [M]+ 397.0250,
[C16H16BrClN4O]
+ requires 397.0274; [α]D
21.5: −20.1 (c 1.0, MeOH);
δH (500 MHz, CDCl3): 7.72 (s, 1H), 7.58 (dd, J = 7.8, 1.2 Hz, 1H),
7.36 (dd, J = 7.8, 1.7 Hz, 1H), 7.30 (m, 1H), 7.19 (m, 1H), 5.63 (d, J
= 15.1 Hz, 1H), 4.33 (d, J = 15.1 Hz, 1H), 4.19 (dd, J = 6.3, 3.8 Hz,
1H), 3.35 (s, 3H), 1.98−1.86 (m, 2H), 0.87 (t, J = 7.6 Hz, 3H).
(R)-2-Chloro-8-(4-bromobenzyl)-7-ethyl-5-methyl-7,8-dihydrop-
teridin-6(5H)-one (22e). 22e was synthesized in 21% yield (white
solid, 35 mg, 0.09 mmol) according to the same procedure as 22a,
from 21 (95 mg, 0.42 mmol) and 1-(bromomethyl)-4-chloro-benzene
(83 μL, 0.50 mmol). HRMS (ESI +ve): found [M]+ 397.0249,
[C16H16Cl2N4O]
+ requires 397.0247; [α]D
22.3: −47.1 (c 1.0, MeOH);
δH (500 MHz, CDCl3): 7.71 (s, 1H), 7.47 (d, J = 8.5 Hz, 2H), 7.18
(d, J = 8.5 Hz, 2H), 5.52 (d, J = 15.1 Hz, 1H), 4.14 (dd, J = 6.3, 3.5
Hz, 1H), 4.10 (d, J = 15.1 Hz, 1H), 3.33 (s, 3H), 1.98−1.90 (m, 1H),
1.86−1.77 (m, 1H), 0.81 (t, J = 7.6 Hz, 3H).
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(R)-2-Chloro-7-ethyl-5-methyl-8-((4-methylthiazol-5-yl)methyl)-
7,8-dihydropteridin-6(5H)-one (22f). 22f was synthesized in 39%
yield (white solid, 41 mg, 0.12 mmol) according to the same
procedure as 22a, from 21 (70 mg, 0.31 mmol) and 5-
(chloromethyl)-4-methyl-1,3-thiazole (HCl salt, 68 mg, 0.37 mmol).
HRMS (ESI +ve): found [M]+ 338.0838, [C14H16ClN5OS]
+ requires
338.0837; [α]D
22.7: −14.5 (c 1.0, MeOH); δH (500 MHz, CDCl3): 8.68
(s, 1H), 7.71 (s, 1H), 5.46 (d, J = 15.5 Hz, 1H), 4.46 (d, J = 15.5 Hz,
1H), 4.27 (dd, J = 6.3, 3.5 Hz, 1H), 3.33 (s, 3H), 2.53 (s, 3H), 2.04−
1.98 (m, 1H), 1.88−1.70 (m, 1H), 0.83 (t, J = 7.4 Hz, 3H).
(R)-8-(3-Chlorobenzyl)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)-
phenyl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one
(23a). 23a was synthesized in 13% yield (white solid, 8.0 mg, 15
μmol) according to the same procedure as 16h, from 22a (40 mg, 110
μmol) and 10a (25 mg, 110 μmol). HRMS (ESI +ve): found [M]+
549.2727, [C30H37ClN6O2]
+ requires 549.2739; [α]D
23.1: +15.2 (c 1.0,
MeOH); δH (500 MHz, CDCl3): 8.16 (d, J = 8.2 Hz, 1H), 7.71 (s,
1H), 7.46 (s, 1H), 7.30−7.27 (m, 2H), 7.23−7.20 (m, 1H), 6.76−
6.70 (m, 2H), 5.58 (d, J = 15.5 Hz, 1H), 4.18−4.09 (m, 4H), 3.50 (d,
J = 11.0 Hz, 2H), 3.36 (s, 3H), 2.69 (s, 3H), 2.69−2.59 (m, 3H), 2.17
(q, J = 12.3 Hz, 2H), 2.00−1.91 (m, 3H), 1.88−1.80 (m, 1H), 1.47 (t,
J = 7.6 Hz, 3H), 0.87 (t, J = 7.0 Hz, 3H).
(R)-3-((2-((2-Ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-
ethyl-5-methyl-6-oxo-6,7-dihydropteridin-8(5H)-yl)methyl)-
benzonitrile (23b). 23b was synthesized in 10% yield (white solid, 6.6
mg, 12 μmol) according to the same procedure as 16h, from 22b (40
mg, 120 μmol) and 10a (26 mg, 110 μmol). HRMS (ESI +ve): found
[M]+ 540.3071, [C31H37N7O2]
+ requires 540.3081; [α]D
24.0: −2.1 (c
1.0, MeOH); δH (500 MHz, CDCl3): 8.08 (d, J = 8.2 Hz, 1H), 7.73
(s, 1H), 7.62−7.55 (m, 3H), 7.47 (t, J = 7.9 Hz, 1H), 7.41 (s, 1H),
6.73−6.69 (m, 2H), 5.55 (d, J = 15.5 Hz, 1H), 4.23 (d, J = 15.5 Hz,
1H), 4.14−4.07 (m, 3H), 3.44 (d, J = 11.7 Hz, 2H), 3.37 (s, 3H),
2.64 (s, 3H), 2.63−2.52 (m, 3H), 2.12 (q, J = 13.2 Hz, 2H), 2.00−
1.91 (m, 3H), 1.86−1.77 (m, 1H), 1.46 (t, J = 6.9 Hz, 3H), 0.87 (t, J
= 7.4 Hz, 3H).
(R)-8-(3-Methoxybenzyl)-2-((2-ethoxy-4-(1-methylpiperidin-4-
yl)phenyl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one
(23c). 23c was synthesized in 32% yield (yellow solid, 20 mg, 37
μmol) according to the same procedure as 16h, from 22c (40 mg, 120
μmol) and 10a (26 mg, 110 μmol). HRMS (ESI +ve): found [M]+
545.3221, [C31H40N6O3]
+ requires 545.3235; [α]D
24.0: +13.2 (c 1.0,
MeOH); δH (500 MHz, CDCl3): 8.19 (d, J = 8.8 Hz, 1H), 7.71 (s,
1H), 7.67 (1H), 7.29−7.26 (m, 1H), 6.91 (d, J = 7.6 Hz, 1H), 6.88−
6.84 (m, 2H), 6.75−6.72 (m, 2H), 5.61 (d, J = 15.1 Hz, 1H), 4.18−
4.09 (m, 4H), 3.77 (s, 3H), 3.61 (d, J = 8.8 Hz, 2H), 3.34 (s, 3H),
2.80−2.69 (m, 2H), 2.75 (s, 3H), 2.67−2.60 (m, 1H), 2.19 (q, J =
12.4 Hz, 2h), 2.02−1.90 (m, 3H), 1.89−1.80 (m, 1H), 1.48 (t, J = 6.9
Hz, 3H), 0.85 (t, J = 7.6 Hz, 3H).
(R)-8-(2-Bromobenzyl)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)-
phenyl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one
(23d). 23d was synthesized in 13% yield (yellow solid, 7.1 mg, 12
μmol) according to the same procedure as 16h, from 22d (36 mg, 91
μmol) and 10a (20 mg, 86 μmol). HRMS (ESI +ve): found [M]+
593.2210, [C30H37BrN6O2]
+ requires 593.2231; [α]D
22.0: −19.39 (c 1.0,
MeOH); δH (500 MHz, CDCl3): 8.06 (d, J = 8.8 Hz, 1H), 7.70 (s,
1H), 7.57 (d, J = 7.6 Hz, 1H), 7.52 (s, 1H), 7.29−7.26 (m, 2H),
7.19−7.16 (m, 1H), 6.72−6.70 (m, 2H), 5.41 (d, J = 16.1 Hz, 1H),
4.30 (d, J = 16.1 Hz, 1H), 4.15 (dd, J = 6.6, 3.8 Hz, 1H), 4.10 (q, J =
6.9 Hz, 2H), 3.54 (d, J = 10.7 Hz, 2H), 3.37 (s, 3H), 2.74−2.60 (m,
6H), 2.17 (m, 2H), 2.02−1.86 (m, 4H), 1.47 (t, J = 6.9 Hz, 3H).
(R)-8-(4-Bromobenzyl)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)-
phenyl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one
(23e). 23e was synthesized in 6% yield (yellow solid, 3.4 mg, 5.7
μmol) according to the same procedure as 16h, from 22e (35 mg, 89
μmol) and 10b (20 mg, 84 μmol). HRMS (ESI +ve): found [M]+
593.2242, [C30H37BrN6O2]
+ requires 593.2234; [α]D
23.4: +6.2 (c 1.0,
MeOH); δH (500 MHz, CDCl3): 8.16 (d, J = 7.9 Hz, 1H), 7.69 (s,
1H), 7.59 (s, 1H), 7.47 (d, J = 8.2 Hz, 2H), 7.20 (d, J = 8.2 Hz, 2H),
6.74−6.69 (m, 2H), 5.51 (d, J = 15.5 Hz, 1H), 4.19−4.09 (m, 4H),
3.58 (d, J = 9.1 Hz, 2H), 3.34 (s, 3H), 2.74 (s, 3H), 2.75−2.59 (m,
3H), 2.19 (m, 2H), 2.02−1.90 (m, 3H), 1.85−1.76 (m, 1H), 1.47 (t, J
= 6.9 Hz, 3H).
(R)-2-((2-Ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-
ethyl-5-methyl-8-((4-methylthiazol-5-yl)methyl)-7,8-dihydropteri-
din-6(5H)-one (23f). 23f was synthesized in 31% yield (yellow solid,
17 mg, 32 μmol) according to the same procedure as 16h, from 22f
(35 mg, 100 μmol) and 10a (23 mg, 100 μmol). HRMS (ESI +ve):
found [M]+ 536.2787, [C28H37N7O2S]
+ requires 536.2802; [α]D
22.8:
−8.3 (c 1.0, MeOH); δH (500 MHz, CDCl3): 8.65 (s, 1H), 8.24 (d, J
= 8.3 Hz, 1H), 7.69 (s, 1H), 7.64 (s, 1H), 6.77 (dd, J = 8.3, 1.8 Hz,
1H), 6.74 (d, J = 1.8 Hz, 1H), 5.47 (d, J = 15.8 Hz, 1H), 4.48 (d, J =
15.8 Hz, 1H), 4.17 (d, J = 6.5, 3.6 Hz, 1H), 4.13 (q, J = 7.0 Hz, 2H),
3.61 (d, J = 10.4 Hz, 2H), 3.32 (s, 3H), 2.75 (s, 3H), 2.75−2.70 (m,
2H), 2.66−2.63 (m, 1H), 2.52 (s, 3H), 2.26−2.15 (m, 2H), 2.03−
1.94 (m, 3H), 1.86−1.76 (m, 1H), 1.49 (t, J = 7.0 Hz, 3H), 0.84 (t, J
= 7.6 Hz, 3H).
ALKF1174L Kinase Assay. ALKF1174L activity was measured in a
LanthaScreen Eu kinase binding assay. The assay was performed in
384-well plates containing ALKF1174L enzyme (5 nM, Carna
Biosciences), Kinase Tracer 236 (30 nM, Thermo Fisher Scientiﬁc),
LanthaScreen Eu-anti-GST antibody (2 nM, Thermo Fisher
Scientiﬁc), either 1% (v/v) dimethyl sulfoxide (DMSO) or the test
compound (in the range from 0.5 nM to 100 μM in 1% (v/v)
DMSO), and assay buﬀer (50 mM N-(2-hydroxyethyl)piperazine-N′-
ethanesulfonic acid (HEPES) pH 7.5; 10 mM MgCl2; 1 mM ethylene
glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid and 0.01%
(w/v) Brij-35; 1 mM dithiothreitol). The reaction was incubated for
60 min at room temperature. The plate was read on an EnVision
multilabel plate reader (PerkinElmer, U.K.) calculating an emission
ratio between the acceptor/tracer emission (665 nM) and the
antibody/donor emission (615 nM). IC50 values were determined
using a nonlinear regression ﬁt of the log(inhibitor concentration)
versus emission ratio with a variable slope equation.
Bromodomain Thermal Shift. BRD4 thermal shift was
measured in a diﬀerential scanning ﬂuorimetry (DSF) assay. The
assay was performed on a Stratagene Mx3005P system quantitative
polymerase chain reaction (qPCR). The assay was performed in 96-
well plates with 20 μL of protein at 2 μM in DSF-assay buﬀer (10 mM
HEPES pH 7.5, 500 mM NaCl) to which 4 μL of Sypro orange dye
and 0.4 μL of 10 μM compound in DMSO was added. The plate was
sealed and centrifuged (1 min, 1000 rpm), and the qPCR machine
was used to detect SYPRO ﬂuorescence while increasing the
temperature from 25 to 95 °C in 71 cycles. The sigmoidal part of
the ﬂuorescence signal was ﬁtted using the Boltzmann equation, the
points of change were deﬁned, and the thermal shift was calculated by
subtracting the protein/DMSO Tm shift from the protein/compound
Tm shift.
BRD4 Isothermal Calorimetry. BRD4 activity was measured by
isothermal calorimetry. The sample cell, sample syringe, and injection
syringe were all equilibrated with gel ﬁltration buﬀer (10 mM HEPES,
150 mM NaCl, 0.5 mM tris(2-carboxyethyl)phosphine (TCEP), 5%
glycerol). The sample syringe was ﬁlled with compound solution
(30−40 μM in gel ﬁltration buﬀer), and the injection syringe was
ﬁlled with protein solution (300 μM in gel ﬁltration buﬀer). After
equilibration of the machine, protein was injected over 21−30
injections, 8 μL each time. For the analysis of the data, the baseline
and integration points were deﬁned to determine binding heats. Data
was ﬁtted to the Boltzmann equation to determine thermodynamic
parameters.
PLK-1 Kinase Assay. All PLK-1 IC50s and percentage inhibitions
at 10 and 100 nM were tested by Thermo Fisher Scientiﬁc in a Ź-
LYTE activity assay using their SelectScreen biochemical kinase
proﬁling service.
Kinase Selectivity Proﬁling. Compound X was assayed at 1 μM
in the DiscoveRx KINOMEscan (scanEDGE) assay platform. The
results for single-concentration binding interactions are reported as
“%Ctrl” (DMSO = 100%Ctrl), where lower numbers indicate stronger
hits.
Immunoassay and Immunoblotting. The human neuro-
blastoma Kelly cell line was maintained in RPMI with 10% fetal calf
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serum. For dose−response experiments, cells were seeded into 10 cm
dishes and, following attachment, treated with the indicated
compound concentration in fresh media. After 3 h, the plates were
transferred onto ice, the media were taken oﬀ, and the cells were
washed once with ice-cold phosphate-buﬀered saline (PBS), before
adding 5% CHAPS lysis buﬀer. After 20 min in lysis buﬀer, cells were
scraped, transferred into Eppendorfs, and spun at 4 °C for 12 min at
12 000 rpm. The supernatant was transferred to a fresh tube, and the
protein content was quantiﬁed using the Direct Detect system
(Millipore). For ALK immunoassay analysis, 15 μg of protein per well
was added in duplicate for each sample to measure either total or
pY1586 ALK, and for immunoblotting, 5 μg of denatured lysates were
loaded into 4−12% Bis/Tris gels, both according to previously
published methods.37
Crystallization, Data collection, and Processing. Puriﬁed
protein in 25 mM HEPES pH 7.5, 300 mM NaCl, 0.5 mM TCEP, 5%
glycerol was cocrystallized with compounds in 1:3 molar ratio at 293
K using sitting drop vapor diﬀusion. Reservoir solutions contained
25% poly(ethylene glycol)3350, 0.2 M ammonium sulfate, 0.1 M Bis−
Tris pH 6.5 or 30% pentaerythritol ethoxylate 15/4, 0.05 ammonium
sulfate, 0.1 M Bis−Tris pH 6.5 respectively.
Diﬀraction data were collected at the SLS X06S overlaid with X-ray
A and BESSY II 14.2 and processed using either XDS (PMID
20124692) or iMOSFLM (PMID 28569763). The data was scaled
using aimless from the CCP4 suite (PMID 29533233) and phased
with PHASER (PMID 28573584) using PDB ID 4OGI (PMID
24584101) as initial model. Manual model rebuilding alternated with
structure reﬁnement was performed in COOT (PMID 28291755)
and REFMAC (PMID 15572771), respectively. Geometry of the ﬁnal
models was veriﬁed using MolProbity (PMID 29067766). Data
collection and reﬁnement statistics are summarized in Supp. Table 3.
NanoBRET Target Engagement Assay. The NanoBRET target
engagement assay in principle was performed as described
previously.38,39 The full-length ALK and BRDBD1 plasmid containing
C-terminal placements of NanoLuc were obtained by the
manufacturer (Promega). To lower intracellular expression levels of
the reporter fusion, the NanoLuc/kinase fusion construct was diluted
into carrier DNA (pGEM3ZF-, Promega) at a mass ratio of 1:10
(mass/mass), prior to forming FuGENE HD complexes according to
the manufacturer’s instructions (Promega). DNA−FuGENE com-
plexes were formed at a ratio of 1:3 (μg DNA/μL FuGENE). One
part of the transfection complexes was then mixed with 20 parts (v/v)
of HEK293T cells suspended at a density of 2 × 105/mL in
Dulbecco’s modiﬁed Eagle’s medium (Gibco) + 10% fetal bovine
serum (GE Healthcare), seeded into T75 ﬂasks, and allowed to
express for 20 h. For target engagement, both serially diluted test
compound and NanoBRET Kinase Tracer K5 (ALK) and BRD-
Tracer (BRD4BD1) (Promega) at a ﬁnal concentration of 2 and 0.5
μM, respectively, were pipetted into white 96-well plates (Corning
3600). The corresponding ALK or BRD4BD1-transfected cells were
added and reseeded at a density of 2 × 105/mL after trypsinization
and resuspending in Opti-MEM without phenol red (Life
Technologies). The system was allowed to equilibrate for 2 h at 37
°C/5% CO2 prior to BRET measurements. To measure BRET,
NanoBRET NanoGlo substrate + extracellular NanoLuc inhibitor
(Promega) was added as per the manufacturer’s protocol, and ﬁltered
luminescence was measured on a CLARIOstar plate reader (BMG
Labtech) equipped with a 450 nm band-pass ﬁlter (donor) and a 610
nm low-pass ﬁlter (acceptor). Competitive displacement data were
then graphed using GraphPad Prism 7 software using a four-
parameter curve ﬁt with the following equation: Y = bottom + (top −
bottom)/(1 + 10((Log IC50 − X) × HillSlope)).
Western Blot Analysis. Protein extracts of cells were prepared by
lysis in radioimmunoprecipitation assay buﬀer (Sigma) supplemented
with protease inhibitors (complete protease inhibitor cocktail,
Roche). Protein extracts (25 μg) were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred onto
poly(vinylidene diﬂuoride) membranes using the Trans-Blot Turbo
transfer system (BioRad). After blocking with 5% bovine serum
albumin in PBS with 0.1% Tween-20 for 30 min, the membrane was
incubated with primary antibodies for 1 h at room temperature.
Horseradish peroxidase-linked secondary antibodies were incubated
30 min at room temperature followed by enhanced chemilumines-
cence (ECL) detection (ECL Western blot substrate, Pierce).
Antibodies. Primary antibodies were obtained from the following
sources: PLK-1 (05-844) and phosphohistone H3 (Ser10) (05806)
from Millipore; pPlk1-T210 (5472) from Cell Signaling; pPlk1-S137
(21738) from Abcam; and cyclin B1 (GNS1) and β-actin (A2228)
from Sigma-Aldrich served as loading control.
Docking. Docking studies were performed using Glide,
Schrödinger, LLC, New York, NY, 2018. Preparation of ALK using
PDB codes 2XB7 was performed using Schrödinger Suite 2018-3
Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, NY,
2018, and preparation of ligands was performed using LigPrep,
Schrödinger, LLC, New York, NY, 2018.
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